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ABSTRACT 
AARON R. THORNER: Determining the Roles of MYB Family Transcription Factors in 
Breast Tumorigenesis 
(Under the direction of Charles M. Perou) 
 
 A major advancement in the field of breast cancer research was the discovery of the 
breast tumor intrinsic subtypes made through the utilization of gene expression microarrays.  
Breast cancer can no longer be viewed as a single disease, but rather as at least five different 
diseases each with unique biological activity and clinical outcomes.  Targeted therapy 
strategies are now employed to treat the different tumor types, such as estrogen receptor 
modulators for ER-positive disease, and HER2-inhibitors for the treatment of HER2-positive 
tumors.  For tumors lacking therapeutic targets, patients are limited to cytotoxic 
chemotherapy regimens.  Consequently, additional research is crucial in further elucidating 
the molecular pathways governing each breast tumor subtype.  
 Over one thousand genes are used to stratify the intrinsic molecular subtypes; 
however, very few of these genes have been analyzed for their direct role in tumorigenesis.  
This dissertation focuses on investigating two intrinsic genes, B-Myb and c-Myb, which are 
both members of an evolutionarily conserved gene family first identified as transforming 
genes in avian viruses.  B-Myb is highly expressed in basal-like tumors, whereas c-Myb is 
highly expressed in luminal tumors.  We applied in vitro and in vivo analyses to ascertain the 
roles of these genes within the molecular subtypes.   
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 High B-Myb expression levels were predictive of poor outcomes across all breast 
tumors and within subtypes.  Mammary epithelial cells expressing high levels of B-Myb were 
more sensitive to topoisomerase 2α inhibitors, but not other chemotherapeutics, via the 
induction of G2/M cell cycle genes including TOP2A itself.  We identified the first published 
B-Myb germline variant causing an increased risk for basal-like disease.   
 We found that the c-Myb oncogene was behaving as a tumor suppressor in luminal 
breast cancer through a novel p53 stabilization pathway.  These results have significant 
treatment implications in light of an ongoing hematologic malignancies clinical trial in which 
c-Myb is targeted for knock-down through antisense oligonucleotides.  These results point to 
both B-Myb and c-Myb as important breast cancer biomarkers with potential clinical 
importance for determining disease risk and guiding treatment, and provide important insight 
into the roles of MYB family proteins in the etiology of breast cancer.   
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CHAPTER I 
INTRODUCTION 
 Breast cancer is the second leading cause of cancer death worldwide and 
approximately one in eight women in the United States will develop invasive breast cancer in 
her lifetime.  The incidence of breast cancer over the past several years has been increasing, 
partially due to breast cancer awareness campaigns promoting frequent screenings, and 
increased longevity; however, the mortality rate has decreased thanks to dramatic 
improvements in patient care and early detection.  One of the major treatment advances has 
been in the identification of the estrogen receptor and drugs that target this protein/pathway; 
specifically, patients with estrogen receptor positive disease are treated with selective 
estrogen receptor modulators, such as tamoxifen, to prevent recurrence, and/or aromatase 
inhibitors, which are a class of drug used to reduce circulating estrogen.  There have also 
been significant improvements in the treatment of estrogen receptor negative breast cancer 
using targeted therapies, such as trastuzumab, which is a monoclonal antibody directed 
against HER2-positive breast cancer.  Lastly, cytotoxic chemotherapy is still the standard of 
care for many patients today.  Despite these treatment advancements approximately 40,000 
women in the U.S. die of breast cancer each year; therefore additional studies and 
improvements are still needed.   
 A better understanding of the molecular etiology of breast cancer is of utmost 
importance in order to discover novel therapeutic targets.  Therefore, my research has 
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focused on the MYB family of transcription factors, specifically the genes B-Myb and c-Myb.  
These genes have implications in other tumor types, and are highly expressed in distinct 
subsets of breast tumors.  Identifying the contributions of both B-Myb and c-Myb to 
mammary tumorigenesis may improve upon our current understanding of breast cancer 
disease progression and could lead to improvements in both disease prediction and patient 
treatment.  
 
Normal Breast Development 
 To better understand mammary carcinogenesis, comprehension of mammary 
development is imperative.  The human breast is a dynamic organ that undergoes several 
dramatic hormone and growth factor-directed changes in shape, size, and function throughout 
a woman’s lifetime (Howard and Gusterson, 2000; Russo and Russo, 2004).  The fact that 
mammary cells are in this continuous state of flux increases the likelihood of tumorigenesis. 
 The mammary gland arises early in utero from an epithelial ectodermal bud that 
invades into the dermis (Parmar et al., 2002).  At the time of birth, the infant breast consists 
of a primitive, blunt-ended, ductal system comprised of one or two inner layers of luminal 
(epithelial) cells, and one layer of myoepithelial cells surrounding the lumen (Russo and 
Russo, 2004).  The postnatal mammary gland, no longer influenced by the mother’s 
hormones, undergoes differentiation and involution by the age of two, leaving small tubular 
structures surrounded by fibroblastic stroma (Anbazhagan et al., 1991).  The prepubescent 
gland remains relatively unchanged until the start of puberty. 
 Both the ductal epithelium and the surrounding stroma (a support structure consisting 
of fibroblasts, endothelial cell, lymphocytes, and adipocytes) transform during puberty.  At 
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this time, there is a dramatic increase in adipose and fibroblastic tissue, and the ducts 
elongate and branch, terminating with the future β-casein (milk)-producing cells in the 
terminal duct lobular units (TDLUs), or “alveolar buds” (Villadsen, 2005).  The adult 
mammary gland consists of a main lactiferous duct attached to the nipple that branches into 
15-25 milk ducts, which further branch into many sub-segmental ducts.  It is continually 
influenced by hormones, with each ovulation promoting a small amount of additional 
budding.   
Three major cell lineages comprise the ducts: the luminal epithelial cells lining the 
inside of the duct, the myoepithelial cells, which form the basal layer of the duct and 
surround the luminal epithelial cells, and the milk-producing luminal-alveolar epithelial cells 
localized to the TDLUs.  Several markers are commonly used to distinguish the mature 
luminal and myoepithelial cells by immunohistochemistry including α-smooth muscle actin 
(SMA), and cytokeratins 5/6 and 17 for the myoepithelial cells, and for luminal cells, 
estrogen receptor alpha (ERα), GATA-3, and cytokeratins 8/18 (Figure 1.1). 
 During pregnancy there occurs a substantial increase in the number of alveoli as well 
as novel formation of lobules by budding from TDLUs (Villadsen et al., 2007).  After birth, 
milk is produced by the alveolar cells in the TDLUs, which is then secreted into the ducts and 
flows to the nipple.  After weaning, the postlactational TDLUs and acini (clusters of milk-
producing lobules) undergo apoptosis during involution.  Finally, during postmenopausal 
involution, the number of both ducts and lobules are reduced (Howard and Gusterson, 2000).  
The extensive remodeling this organ undergoes throughout a woman’s lifespan suggests the 
existence of a mammary stem cell. 
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Figure 1.1.  Immunohistochemistry of a normal, human mammary gland. 
Tissue stained for proteins uniquely expressed in luminal epithelial cells (ER, 
GATA3, CK 8/18), or myoepithelial cells (SMA, CK17, CK 5/6).  ER: 
estrogen receptor alpha, CK: cytokeratin, SMA: alpha-smooth muscle actin 
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Breast Cancer Molecular Subtypes 
 Breast cancer is a heterogeneous disease pathologically, molecularly, and clinically.  
Over the past decade, the use of gene expression microarrays by our lab and others has 
revealed the existence of at least six molecular subtypes of breast cancer (Herschkowitz et 
al., 2007; Hu et al., 2006; Parker et al., 2009; Perou et al., 2000; Sorlie et al., 2003).  These 
subtypes include luminal A, luminal B, normal breast-like, HER2-enriched, basal-like, and 
claudin-low, each with unique gene expression profiles (Figure 1.2) and distinct clinical 
outcomes (Figure 1.3).  The molecular subtypes were initially identified using a 496 
“intrinsic” gene set; these were genes whose expression varied greatly between different 
tumors, but showed little variation between paired samples of the same tumor (Perou et al., 
2000).  More recently, our lab has created a 50-gene subtype predictor (PAM50) which adds 
significant prognostic and predictive information to the commonly used clinical parameters 
for breast cancer patients (Parker et al., 2009). 
 The foremost determinant of subtype is the presence or absence of estrogen receptor-
alpha (ESR1/ER) expression.  Both luminal A and luminal B tumors are ER-positive and 
comprise the majority (60-80 percent) of breast cancer cases.  The luminal A tumors have 
markedly high gene expression of the transcription factors GATA3, XBP1, FOXA1, (Lacroix 
and Leclercq, 2004) and cytokeratins 8 and 18.  The luminal B tumors also express these 
genes, but at lower levels, and additionally have high expression of the “proliferation gene 
signature”; this is a dominant gene signature that is a marker of cell proliferation rates across 
of variety of tumor types (Hu et al., 2006; Whitfield et al., 2006).  Normal breast-like tumors 
cluster with the ER-positive subtype and have similar gene expression patterns to normal  
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Figure 1.2.  Breast tumors hierarchical clustered using the intrinsic gene list.  
A combined data set of 324 tumor samples collected at UNC was clustered using 
the intrinsic gene set (Hu et al., 2006). Clustering identified the six major intrinsic 
subtypes: luminal A, luminal B, normal breast-like, basal-like and HER2-enriched, 
and claudin-low.  
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Figure 1.3.  Kaplan-Meier plot depicting overall survival for each subtype. 
 
tissue, most likely due to the tumor specimens containing high amounts of “contaminating” 
normal mammary tissue. 
The ER-negative subtypes consist of the HER2/ERBB2-enriched, basal-like, and 
claudin-low tumors.  The HER2-enriched tumors overexpress HER2 and are typically 
amplified at this locus at the DNA level.  Basal-like disease makes up 10-15 percent of breast 
carcinomas and was named “basal-like” due to the observed high expression of cytokeratins 
5 and 17; cell surface markers expressed in normal mammary basal/myoepithelial cells.  
However, it is likely that this tumor type is derived from luminal epithelium and not 
myoepithelium, as malignant myoepithelioma of the breast is known to arise from the 
myoepithelial cell population and is an extremely rare tumor (Sauer, 2007).  Basal-like 
tumors are sometimes referred to clinically as “triple-negative” tumors due to the absence of 
Months 
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immunohistochemical staining for ER, progesterone receptor (PR), and HER2, although this 
is not true of all basal-like tumors (Carey et al., 2007).  Tumors of this subtype also have 
high expression of the proliferation gene signature.  The recently identified claudin-low 
subtype is ER-negative and is defined by low expression of tight junction and cell-to-cell 
adhesion proteins including claudins 3, 4, 7, occludin, and E-cadherin (Herschkowitz et al., 
2007).  Claudin-low tumors share features with both normal mammary stem cells, including 
low expression of EpCAM and mucin-1 (Hennessy et al., 2009), and also mammary tumor 
initiating cells, which are described by the cell surface markers CD24lo, CD44+ (Al-Hajj et 
al., 2003). 
 
Mammary Cellular Hierarchy and Relevance to Molecular Subtypes 
Breast cancer was studied as one disease for many decades.  However, data collected 
over the past several decades, notably gene expression analysis, has revealed that breast 
cancer not one disease, but rather a group of complex diseases described above.  The 
molecular subtyping of breast cancer also allows us to study the etiology of each tumor type.  
The mammary epithelial cell population most likely exists as a hierarchy of cell types, from 
undifferentiated stem cells, to mature luminal cells, and the molecular subtypes may reveal 
clues as to the cell-of-origin for each tumor type. 
 Many, if not all, human organs are made up of a cellular hierarchy, from 
undifferentiated, tissue-specific stem cells, through lineage-specific progenitors, and finally 
mature, differentiated cells that make up the bulk of the organ.  Current evidence suggests 
this to also be true for the mammary gland epithelium.  It has been hypothesized that an ER-
negative stem cell can self-renew or undergo differentiation leading to committed progenitor 
populations (it is unknown how many progenitor types) that will eventually give rise to the 
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myoepithelial, ductal epithelial, and alveolar cell populations that comprise the epithelial 
component of the breast (Dontu et al., 2004).  The mammary stem cell was also reported as 
not expressing the progesterone receptor, or keratins 8/18 (luminal markers), but did express 
keratins 5/6 and 14 (basal markers).  This is in contrast to the luminal progenitor population 
which expresses both basal keratins 5/6 and luminal keratins 8/18 (Figure 1.4) (Boecker and 
Buerger, 2003; Clarke, 2005; Livasy et al., 2005; Woodward et al., 2005).  Finally, the 
mature luminal cells express ER, GATA3 and luminal keratins 8/18, with the luminal 
alveolar cells expressing milk protein in addition to these genes. 
 It has been reported that many cancers contain, and are driven by, tumor stem cells; a 
rare cell population within the bulk of the tumor with the capacity for limitless self-renewal 
and the ability to promote tumor formation (Clarke et al., 2006; Jordan et al., 2006; Reya et 
al., 2001; Wicha et al., 2006).  Human mammary tumor stem cells have been isolated using 
CD44+ and CD24- (Al-Hajj et al., 2003; Shipitsin et al., 2007).  Also, ALDH1A1 (aldehyde 
dehydrogenase 1 family, member A1)-positive cells from the normal human mammary gland 
were capable of mammosphere formation (an in vitro assay used to determine stem cell 
potential) as well as mammary structure formation in a humanized mouse mammary gland, 
suggesting ALDH1A1 is expressed in the normal and tumor stem cell populations (Ginestier 
et al., 2007). 
Based on cell surface marker expression as well as recent complex gene expression 
analyses comparing gene expression signatures of normal mammary epithelial populations to 
breast tumor gene expression patterns has led to a hypothetical model of breast tumor cell-of-
origin (Figure 1.4) (Lim et al., 2009; Prat and Perou, 2009).  However, it is possible that  
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Figure 1.4.  Current model of mammary cell differentiation.  Immunohistochemical 
markers known to stain positive are in parenthesis for each cell type.  Cell surface markers 
used in isolation of various lineages are noted in red.  Hypothetical tumor cell-of-origin noted 
by bar on right.  Cell images were created by Jason Herschkowitz.  Figure was also adapted 
from Visvader, 2009 and Pratt and Perou, 2009.    
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tumor gene expression may not reflect that of the cell-of-origin, and it is still necessary to 
validate these correlative findings experimentally. 
 
MYB Family of Transcription Factors 
 Many genes are differentially expressed across the breast tumor molecular subtypes, 
however, the contribution of the vast majority of these genes to tumorigenesis is unknown.  
The vertebrate MYB family of nuclear transcription factors consists of three members: MYB 
(c-Myb), MYBL1 (A-Myb), and MYBL2 (B-Myb) (Figure 1.5A), all of which are found in 
the intrinsic gene set (Hu et al., 2006) and all of which show distinctive expression 
signatures. It is these distinctive signatures that and previously known importance of this 
gene family that caused us to study these genes in depth in order to better define their roles in 
breast development and tumorigenesis. 
 The c-Myb proto-oncogene was first identified as the mammalian homolog of v-myb, 
which is the transforming gene transmitted by the avian myeloblastosis and E26 retroviruses 
that causes acute leukemia in birds (Klempnauer et al., 1982; Leprince et al., 1983).  A- and 
B-Myb were later discovered during low stringency screening of human cDNA libraries with 
a c-Myb probe (Nomura et al., 1988).  Found in the genomes of both plants and animals, the 
MYB genes are conserved throughout evolution and control processes from flavonoid 
production to cellular proliferation (Ito et al., 2001; Rosinski and Atchley, 1998).  In contrast 
to vertebrates, invertebrates contain only one MYB protein, which in Drosophila (dMYB) is 
phylogenetically and functionally complementary to vertebrate B-Myb, suggesting B-Myb to 
be the most ancient family member (Figure 1.5A) (Davidson et al., 2005).  
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(A) 
 
(B) 
 
 
Figure 1.5.  MYB family proteins.  (A) Phylogram depicting the evolutionary relationships 
between drosophila, human, and mouse MYB proteins (ClustalW v.1.83). (B) Protein 
structural homologies between MYB family members.  Color bars indicate conserved 
domains between the three family members.  Percentages represent sequence homology 
relative to c-Myb.  The DNA binding region consists of three DNA binding domains (DBD) 
recognizing the consensus sequence PyAAC(G/T)G. TA: transcriptional activation domain.  
Figure adapted from (Ness, 2003; Oh and Reddy, 1999; Rosinski and Atchley, 1998; Weston, 
1998).   
  
13 
 
All three human MYB protein sequences are highly conserved, with over 60% amino 
acid sequence identity (Figure 1.5B).  The protein structure can be divided into three major 
domains: DNA-binding, transcriptional activation, and regulatory (Ness, 2003).  The highest 
sequence homology (~90%) between the three members is found near the amino-terminus of 
the protein (residues 1-200), which contains three “MYB DNA binding domains”.  Each  
domain consists of approximately 50 amino acids with the ability to recognize and bind to 
the DNA consensus sequence PyAAC(G/T)G (Rosinski and Atchley, 1998).  The carboxyl- 
terminal end of the protein contains the regulatory domain and shares the second highest, 
albeit small, region of homologous sequence.  This domain contains residues which, upon 
phosphorylation or other modification, confer a conformational change allowing for 
transactivation (Weston, 1998).  Finally, the central region of the MYB family proteins 
contains the transcriptional activation domain.  This domain has the least sequence homology 
between the three family members and may allow for protein-protein interactions with 
unique transcriptional co-factors to alter transcriptional activity (Sala, 2005).  For example, 
B-Myb is induced during late G1/S-phase and the regulatory domain is phosphorylated by 
CDK2 and mitotic cyclins to activate its ability to interact with DNA and promote 
transcription of cell cycle genes (Sala, 2005). 
In vitro studies have shown that each family member has the ability to transactivate 
genes containing the MYB DNA consensus sequence; however, varying tissue-specific 
expression patterns of each protein suggests distinct biological roles. Until recently, the 
expression of c-Myb was largely observed to occur in early lineage hematopoietic cells.  
Mice homozygous null for c-Myb die by embryonic day 15 (E15) due to severe anemia 
caused by improper erythropoiesis (Mucenski et al., 1991).  A-Myb expression is also 
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confined to specific tissue types, namely germinal B lymphocytes, the developing central 
nervous system, the male reproductive system, and the proliferating mammary gland (Ness, 
2003; Trauth et al., 1994).  A-Myb knockout mice are viable; however, males are sterile due a 
defect in spermatogenesis, and females cannot feed their pups due to a lack of ductal 
proliferation in the mammary gland during pregnancy (Toscani et al., 1997).  In contrast to c-
Myb and A-Myb, the expression of B-Myb is ubiquitous to virtually all proliferating cells and 
plays an essential role in vertebrate development (Sala, 2005).  Knocking out murine B-Myb 
causes early embryonic lethality (E4.5-6.5) resulting from unsuccessful inner cell mass 
formation, suggesting a possible role for B-Myb in embryonic stem cells (Tanaka et al., 
1999). 
Since MYB transcription factors play significant roles in cell proliferation, and in fact 
one MYB protein is a viral transforming protein, the altered expression of these proteins has 
been observed and implicated in a variety of tumors.  Amplification of the B-Myb locus 
(20q13) is frequently found in breast, liver, ovarian, and prostate tumors (Sala, 2005).  This 
gene is listed in the top 5 “markers of treatment failure” of embryonal tumors of the central 
nervous system (CNS) and high expression of B-Myb in cancer generally correlates with poor 
patient outcomes (Pomeroy et al., 2002).  However, the roles of B-Myb in breast tumor 
progression, as well as its mammary transcriptional targets, and the significance of its 
expression during treatment, are still poorly understood. 
Amplification of the c-Myb oncogene locus at 6q22-23 is observed in a variety of 
tumors including T-cell leukemia, acute myelogenous leukemia, colon cancer, and adenoid 
cystic carcinomas of the head, neck and breast (Oh and Reddy, 1999; Persson et al., 2009).  
c-Myb has been implicated in progenitor cell maintenance in the hematopoietic system, 
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neuroblastoma cell cultures, and colonic crypts (Malaterre et al., 2007; Maurice, 2007; Thiele 
et al., 1988).  In breast cancer it is reported that c-Myb expression is increased in ERα-
positive tumors and its locus is amplified in some (29%) hereditary, BRCA1-mutant breast 
tumors (Guérin M, 1990; Kauraniemi et al., 2000).  c-Myb was observed by us, and others, to 
be highly expressed in virtually all ER+/luminal tumors and is sporadically found highly 
expressed in a few basal-like tumors, consistent with previously reported data for BRCA1-
associated tumors (which tend to be basal-like).  The function of the c-Myb oncogene in 
breast cancer is not well studied.  Understanding the contribution of c-Myb to the 
ER+/luminal tumors may lead to better treatment options for patients with this disease. 
 
Research Introduction 
A great deal of direct and indirect evidence suggests that the altered 
expression/function of MYB family of proteins can contribute to tumorigenesis.  In breast 
tumors, we have observed distinct expression patterns for each MYB family member with 
different tumor subtypes showing very high expression is some subtypes and low to absent 
expression in others.  We hypothesize that altered expression levels of B-Myb or c-Myb in the 
mammary gland in vivo may contribute to faster tumor formation, or decreased tumor 
latency, and therefore, we tested these hypotheses using a combination of in vitro and in vivo 
methods to determine the role of the MYB family members in breast tumorigenesis.  
Chapters two and three are devoted to evaluating the in vitro and in vivo roles of altered 
expression of B-Myb and c-Myb, respectively. 
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CHAPTER II 
IN VITRO AND IN VIVO ANALYSIS OF B-MYB IN BASAL-LIKE BREAST CANCER 
 
PREFACE 
 This work was previously published.  My role in this project included initiating, 
organizing, and designing the study.  I performed the microarray data analysis, B-Myb over-
expression in mammary cell lines experiments including cell line chemotherapy treatments, 
and flow cytometry assays.  I initiated all aspects of manuscript preparation, including 
writing, figure preparation, and revisions.  Katherine A. Hoadley aided in study design and 
contributed writing of the manuscript.  Joel S. Parker assisted with microarray analysis.  
Robert C. Millikan and Scott Winkel were essential in the collection and analysis of the 
Carolina Breast Cancer Study patient samples.  Charles M. Perou was the principal 
investigator, conceived the project, and contributed to writing the manuscript. 
 
Thorner AR, Hoadley KA, Parker JS, Winkel S, Millikan RC, Perou CM (2009).  In vitro and 
in vivo analysis of B-Myb in basal-like breast cancer. Oncogene 28: 742-51. 
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ABSTRACT 
 A defining feature of basal-like breast cancer, a breast cancer subtype with poor 
clinical prognosis, is the high expression of “proliferation signature” genes.  We identified B-
Myb, a MYB family transcription factor that is often amplified and overexpressed in many 
tumor types, as being highly expressed in the proliferation signature.  However, the roles of 
B-Myb in disease progression, and its mammary-specific transcriptional targets, are poorly 
understood.  Here, we demonstrated that B-Myb expression is a significant predictor of 
survival and pathological complete response to neoadjuvant chemotherapy in breast cancer 
patients.  We also identified a significant association between the G/G genotype of a 
nonsynonymous B-Myb germline variant (rs2070235, S427G) and an increased risk of basal-
like breast cancer [OR 2.0, 95% CI (1.1-3.8)].  In immortalized, human mammary epithelial 
cell lines, but not basal-like tumor lines, cells ectopically expressing wild-type B-Myb or the 
S427G variant showed increased sensitivity to two DNA topoisomerase IIα inhibitors, but 
not to other chemotherapeutics.  In addition, microarray analyses identified many G2/M 
genes as being induced in B-Myb overexpressing cells.  These results confirm that B-Myb is 
involved in cell cycle control, and that dysregulation of B-Myb may contribute to increased 
sensitivity to a specific class of chemotherapeutic agents.  These data provide insight into the 
influence of B-Myb in human breast cancer, which is of potential clinical importance for 
determining disease risk and for guiding treatment.  
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INTRODUCTION 
Breast cancer is not one disease, but rather, represents at least six subtypes (Hu et al., 
2006; Perou et al., 2000; Sorlie et al., 2003).  These include luminal A, luminal B, normal-
like, HER2-enriched, claudin-low and basal-like, each with unique gene expression profiles 
and distinct clinical outcomes.  The majority of breast cancer cases (60-80 percent) comprise 
the luminal/estrogen receptor-α positive (ER+) tumors, while basal-like breast carcinoma 
accounts for 10-15 percent of all cases.  The basal-like subtype, often clinically observed as 
“triple-negative” tumors (negative for ERα, PR, and HER2), is of particular interest because 
treatment options are limited to chemotherapy only and patients with this disease typically 
have poor outcomes.  One contribution to the poor outcome of basal-like breast cancer 
patients may be their high cellular proliferation rates, which is manifested transcriptionally as 
the high expression of the “proliferation signature”; this is a dominant gene signature that is a 
marker of cell proliferation rates across multiple tumor types (Hu et al., 2006; Whitfield et 
al., 2006).  B-Myb, a gene with known cell cycle control functions and implications in 
tumorigenesis (Sala, 2005), is one of approximately 100 genes that define the proliferation 
signature. 
B-Myb is a member of the vertebrate MYB family of nuclear transcription factors.  In 
humans this family is comprised of A-Myb (MYBL1), B-Myb (MYBL2), and c-Myb (MYB).  
Each family member is able to recognize and bind to the same DNA consensus sequence 
(PyAAC(G/T)G) to promote gene transcription; however, varying tissue-specific expression 
patterns, as well as protein-protein interactions with unique co-factors, suggests that distinct 
biological roles exist for each MYB family member (Rosinski and Atchley, 1998; Sala, 
2005).  Found in the genomes of both plants and animals, MYB proteins are conserved 
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throughout evolution and control processes from flavonoid production to cellular 
proliferation (Ito et al., 2001; Rosinski and Atchley, 1998).  In contrast to vertebrates, 
invertebrates contain only one MYB protein, which in Drosophila (dMYB) is 
phylogenetically and functionally complementary to vertebrate B-Myb, suggesting B-Myb to 
be the most ancient family member  (Davidson et al., 2005).  The expression of B-Myb, 
unlike c-Myb and A-Myb (Malaterre et al., 2007; Mucenski et al., 1991; Ness, 2003; Toscani 
et al., 1997; Trauth et al., 1994), is ubiquitously expressed in virtually all proliferating cells 
as a regulator of cell cycle progression and plays an essential role in vertebrate development; 
knocking out murine B-Myb causes early embryonic lethality (E4.5-6.5) resulting from 
unsuccessful inner cell mass formation (Tanaka et al., 1999). 
MYB family members have been implicated in tumorigenesis for several decades.  
The c-Myb proto-oncogene was first identified as the mammalian homolog of v-myb, which 
is the transforming gene transmitted by the avian myeloblastosis and E26 retroviruses 
causing acute leukemia in birds (Klempnauer et al., 1982; Leprince et al., 1983).  A- and B-
Myb were later discovered during low stringency screening of human cDNA libraries 
(Nomura et al., 1988).  The B-Myb chromosomal locus, 20q13, is amplified and/or highly 
expressed in a variety of tumor types including breast, prostate, liver and ovarian carcinomas, 
and in most cases this high expression portends a poor prognosis (Sala, 2005).  B-Myb is also 
an important marker of poor outcome in embryonal tumors of the central nervous system 
(CNS) (Pomeroy et al., 2002).  Recently, a nonsynonymous B-Myb germline variant 
(rs2070235) causing a serine to glycine amino acid change (S427G) was linked to a decrease 
in overall cancer risk for neuroblastomas, chronic myelogenous leukemia, and colon cancers 
in a combined dataset of cases and controls (Schwab et al., 2007).  However, the molecular 
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roles of B-Myb in disease progression, as well as its transcriptional target genes in the 
mammary gland, are still poorly understood.  To gain insight into B-Myb and its involvement 
in breast cancer, we analyzed the expression of B-Myb across the breast cancer subtypes, 
examined its relationship to survival and pathological complete response and the correlation 
of variant rs2070235 to disease risk.  We also manipulated the expression of B-Myb and the 
S427G variant in normal and tumor derived mammary cell lines and observed alterations in 
drug sensitivity and cell cycle profiles. 
 
MATERIALS AND METHODS 
Cell Lines.  hTERT-immortalized, human mammary epithelial cell lines (HME-CC, 
ME16C), and basal-like breast cancer-derived lines (SUM102, SUM149) were cultured as 
described (Hoadley et al., 2007; Troester et al., 2004). Full-length, human B-Myb cDNA 
(GenBank NM_002466) was cloned into the pBabe.puro.GWrfA (Gateway Reading Frame 
A) vector using Gateway® Cloning Technology (Invitrogen, Carlsbad, CA, USA).  
Retrovirus was produced in Phoenix 293T cells by transfecting with ten micrograms of 
vector using Lipofectamine 2000 (Invitrogen), as per manufacturer’s instructions.  Media 
was changed 24 hours post-transfection and supernatants collected 12 hours later.  Seventy-
five micrograms of polybrene were added to the collected supernatants and applied to the 
mammary cell lines.  Stable populations were selected by culturing in 1 ug/mL puromycin 
for HME-CC and ME16C, or 0.5 ug/mL puromycin for SUM102 and SUM149.   
B-Myb variant (S427G) was created in the pBabe.puro.B-Myb expression vector 
using QuikChange® XL Site-Directed Mutagenesis Kit (Stratagene, Los Angeles, CA, 
USA). 
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Western Blot Analysis.  Cells were grown in 10 cm tissue culture-treated dishes until 80 
percent confluence, followed by harvest, protein isolation and quantification as previously 
described (Troester et al., 2004).  Membranes were probed for B-Myb (sc-725; Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, USA), and β-actin (AC-15; Abcam, Cambridge, MA, 
USA), followed by anti-rabbit or anti-mouse IgG horseradish peroxidase-linked whole 
antibody (Amersham Biosciences) and detected using SuperSignal West Pico 
Chemiluminescent Substrate (Pierce, Rockford, IL, USA). 
 
Cell Cycle Analysis.  Cells were treated with a range of doxorubicin (0-70 nM) or etoposide 
(0-2 nM) doses and DNA content was analyzed using a modified propidium iodide staining 
assay.  Briefly, one million cells were collected by trypsinization, washed in 1x PBS, and 
fixed in 70% ethanol at 4C overnight.  Cells were washed with PBS/0.2% BSA and 
resuspended in 500 microliters of PBS/0.2% BSA and 100 micrograms RNaseA.  Propidium 
iodide was added to a final volume of 50 micrograms, and cells incubated at 37C for 30 
minutes.  DNA content analysis was performed using a FACScan flow cytometer (Becton 
Dickinson, Franklin Lakes, NJ, USA).  To determine fractions of cells in G1 and G2/M 
phases, histograms of DNA content were analyzed using Summit v4.3 software (Dako, 
Carpinteria, CA, USA) gating around 2N and 4N DNA content.  Analyses were done on 
three separate days and mean values were calculated. 
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Cytotoxicity Assay.  Cell line sensitivities to drugs were assessed using a modified 
mitochondrial dye conversion assay (Cell-Titer 96, Promega #G4100, Madison, WI, USA) as 
described (Hoadley et al., 2007; Troester et al., 2004).  Chemotherapeutics (carboplatin, 
doxorubicin, 5-fluorouracil, paclitaxel, etoposide, camptothecin) were purchased from Sigma 
(St. Louis, MO, USA).  The 72-hour inhibitory concentration that caused a 50% reduction in 
MTT dye conversion (IC50) was determined using nonlinear regression (SAS Statistical 
Software, Cary, NC, USA) (Vanewijk and Hoekstra, 1993).  Differences in the IC50 
estimates were tested by a traditional ANOVA test of nested models was performed using the 
R system for statistical computing (R Development Core Team, 2006 http://www.R-
project.org). 
 
Microarray Analysis.  Five replicates each of HME-CC B-Myb-overexpressing and vector 
control cell lines were treated with the 72-hour IC50 dose of doxorubicin.  Poly-A(+) RNA 
was collected (Micro-FastTrack2.0 mRNA Isolation Kit, Invitrogen) from treated control 
cells and B-Myb overexpressing lines, reverse transcribed and labeled using the Agilent Low 
RNA Input Linear Amplification Kit (Agilent Technologies, Santa Clara, CA, USA), and 
hybridized to Agilent Human 44K Custom Oligo microarrays as described (Hu et al., 2005).  
An untreated HME-CC cell line reference was co-hybridized to all arrays (e.g. untreated 
HME-CC vs. doxorubicin-treated empty vector HME-CC).  Microarrays were scanned on an 
Axon Genepix 4000B microarray scanner and analyzed using GenePix Pro 5.1 software 
(Molecular Devices, Sunnyvale, CA, USA).  Data was normalized using Lowess 
normalization on the Cy3 and Cy5 channels.  Microarray data is available at the UNC 
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Microarray Database [http://genome.unc.edu] and at the Gene Expression Omnibus 
(GSE11429). 
 
Microarray Statistical Analyses.  Supervised microarray analysis was performed by 
selecting genes with an absolute signal intensity of at least 30 units in both dye channels and 
data present in at least 70% of experimental samples.  A two-class, unpaired Significance 
Analysis of Microarrays (SAM) was performed to identify significant genes associated with 
B-Myb expression with a false discovery rate (FDR) of less than 3%  (Tusher et al., 2001).   
The Netherlands Cancer Institute breast cancer dataset (NKI-295, n=295) was used 
for analysis of B-Myb expression across breast cancer subtypes (van de Vijver et al., 2002); 
however, only locally-treated tumors (no chemotherapy) were used in survival analyses 
(n=165).  Association of B-myb expression states (rank ordered and split in halves: low/high) 
relative to survival was tested using the Cox-Mantel log-rank test and results visualized using 
Kaplan-Meier survival plots (WinSTAT v.2007.1). Testing the association of B-myb 
expression versus subtypes was performed using ANOVA.  Three other published datasets 
were analyzed, as above, for survival (Miller et al., 2005; Wang et al., 2005) or pathological 
response (Hess et al., 2006) by chi-square using the R system for statistical computing.   
 
Carolina Breast Cancer Study.  The Carolina Breast Cancer Study (CBCS) is a population-
based, case-control study of breast cancer conducted in 24 counties of central and eastern 
North Carolina between 1993 and 2001 (Millikan et al., 2003; Newman et al., 1995). 
Incident cases of primary invasive and in situ breast cancer were identified using the North 
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Carolina Central Cancer Registry, with over-sampling of African-American and younger 
women.  Controls were frequency-matched to cases based upon age (± 5 years) and self-
reported race using randomized recruitment.   Cases were subtyped using a panel of 
immunohistochemistry markers that identified the "intrinsic" breast cancer subtypes (Carey 
et al., 2006; Millikan et al., 2008).  Definitions of subtypes were luminal A (ER+ PR+ 
HER2-), luminal B (ER+PR+HER2+), basal-like (ER-PR-HER2-, ck5/6+ and/or HER1+), 
HER2+ (ER-PR-HER2+), and unclassified (negative for all five markers).  Procedures for 
recruiting and enrolling study participants and obtaining biologic samples were approved by 
the Institutional Review Board of the UNC School of Medicine, and informed consent was 
obtained from each participant. 
 
Genotyping of B-Myb.  Genotyping for the B-Myb polymorphism at codon 427, Serine 
(AGC) to Glycine (GGC) (rs2070235), was conducted using DNA extracted from peripheral 
blood lymphocytes.  The ABI 7700 Sequence Detection System, or "Taqman"™ assay 
(Applied Biosystems, ABI, Foster City, CA, USA) was employed, with polymerase chain 
reaction (PCR) primers and probes designed using Primer Express TM software (ABI) and 
assay conditions based on the allelic discrimination protocol from Applied Biosystems.  PCR 
primer and probe sequences are available upon request.  Out of a total of 3862 samples 
genotyped, the failure rate was 0.4%, and complete agreement was obtained on a 10% 
random sample. 
There were no significant departures from Hardy-Weinberg equilibrium among 
African-American cases (p=0.80), African-American controls (p=0.77), Caucasian cases 
(p=0.27), or Caucasian controls (p=0.51). 
29 
 
Cell line genotyping was performed by Polymorphic DNA Technologies, Inc 
(Alameda, CA, USA).  
 
Genotype Statistical Analysis.  B-Myb genotypes were determined for 1256 cases with 
subtype information (500 African-American, 756 Caucasian) and 1814 controls (679 
African-American, 1135 Caucasian).  Odds ratios (ORs) and 95% Confidence Intervals (CIs) 
for each breast cancer subtype versus all controls were calculated using unconditional logistic 
regression.  The PROC GENMOD statement in SAS (version 8.2; SAS Institute, Cary, NC, 
USA) was used to incorporate offsets derived from sampling probabilities used to identify 
eligible study participants, race (African-American, Caucasian), and age (11-level ordinal 
variable representing 5-year age categories).  Trend tests were conducted by calculating the 
p-value for B-Myb genotype coded as an ordinal variable.  Likelihood ratio tests (LRTs) 
were used to test for modification of ORs by race. 
 
RESULTS 
High B-Myb Expression in Breast Tumors Predicts Poor Outcome.  To assess the 
relevance of B-Myb gene expression across the breast cancer subtypes, breast tumor 
microarray data from the Netherlands Cancer Institute (NKI-295, n=295, (van de Vijver et 
al., 2002)) was analyzed. Tumor samples were classified into five breast cancer subtypes 
using a single sample centroid-based predictor as described (Hu et al., 2006).  An ANOVA 
analysis performed on these stratified samples showed that B-Myb expression differs 
significantly across the subtypes and was highest in basal-like tumors (Figure 2.1).   
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Figure 2.1.  B-Myb expression across breast cancer subtypes.  The NKI 
breast tumor microarray dataset (n=295) was classified into the five 
intrinsic subtypes and box plots used to visualize B-Myb expression 
according to breast cancer subtypes.  Statistical significance was 
calculated by ANOVA.   
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To test for correlations between B-Myb mRNA expression alone and patient outcome, 
we analyzed the NKI patients not receiving adjuvant systemic treatment (i.e. local treatment 
only; n=165).  This allowed us to better identify the prognostic abilities of B-Myb without the 
confounding data of treatment response.  The NKI “local-only” tumors were rank ordered 
into halves (low/high) based on their B-Myb expression levels and analyzed for overall 
survival (OS) and relapse free survival (RFS) by Kaplan-Meier analysis.  Poor OS and RFS 
were highly correlated (p<0.001) with B-Myb high expression levels in these NKI samples 
(Figure 2.2A, and RFS data not shown).  B-Myb expression alone was also able to 
significantly predict OS on local-only treated luminal A subtype tumors (n=72) (Figure 
2.2B), luminal B (n=26) (Figure 2.2C), HER2+/ER- (n=21) (Figure 2.2D), but not basal-like 
tumors (n=30) (Figure 2.3A).  We then evaluated the prognostic ability of B-Myb using two 
other published breast tumor microarray datasets (Miller et al., 2005; Wang et al., 2005).  
Wang et al., 2005 (n=286) consisted of microarrays on untreated, lymph-node-negative 
primary ER+ and ER- breast cancers with relapse data, and B-Myb was capable of predicting 
RFS in these patients (Figure 2.2E).  On this same dataset, B-Myb also predicted RFS in the 
ER+ patient subset (n=209), but not the ER- subset (n=77) (Figures 2.3B, C).  Another 
dataset consisting of primary invasive tumors (Miller et al., 2005) (n=234) was tested and 
similar results were found (Figure 2.2F). 
To determine if B-Myb expression was involved with pathologic complete response 
(pCR), we used the data of Hess et al., 2006, where microarrays were performed on pre-
treatment breast tumors from patients receiving neoadjuvant paclitaxel, followed by 5FU-
Adriamycin-Cyclophosphamide (T/FAC; n=133).  Again, samples were split into two groups  
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Figure 2.2.  High expression of B-Myb correlates with poor sruvival.  Kaplan-Meier 
survival analyses based on B-Myb expression values rank ordered into halves (low/high).  
(A-D) Overall survival (OS) of locally treated NKI tumor samples: (A) All subtypes 
combined (n=165), (B) Luminal A (n=72), (C) Luminal B (n=26), (D) HER2+/ER- (n=21).  
(E) RFS, Wang et al., 2005 (n=286), a locally treated, lymph-node-negative tumor 
microarray dataset.  (F) Miller et al., 2005 breast tumor microarray dataset (n=234).   
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Figure 2.3. 
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Figure 2.3.  High expression of B-Myb correlates with poor outcome.  Kaplan-Meier 
survival analysis based on B-Myb expression values rank ordered and split into halves 
(low/high).  (A) NKI, locally treated, basal-like (n=30).  (B) Wang et al., 2005, ER+ samples 
(n=209).  (C) Wang et al., 2005, ER- samples (n=77).  
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based on B-Myb expression (low/high).  B-Myb high expression was again associated subtype 
(data not shown) and with pCR, as calculated by chi-square test (p=0.008; Table 2.1). 
 
Table 2.1. High B-Myb expression in breast tumors (n=133; Hess et al., 2006) is 
associated with pathological complete response (pCR).  
 
χ2=6.9433, df=1, p-value=0.008. 
 
B-Myb Germline Variant (rs2070235) Increases Risk of Basal-Like Breast Cancer.  A 
nonsysnonymous germline B-Myb variant exists that causes a serine to glycine substitution 
(rs2070235, S427G).  This non-conservative change prompted us to look for correlations 
between this variant and baseline susceptibility risk in the population-based Carolina Breast 
Cancer Study/CBCS (Newman et al., 1995).  Odds ratios for the B-Myb genotype and all 
breast cancer cases, luminal A, and basal-like cases, versus controls are presented in Table 
2.2.  There was no association between B-Myb genotype and all breast cancer (p=0.71); 
however a statistically significant association was observed for basal-like breast cancer 
(p=0.047), but not luminal A (p=0.14).  No association was observed for B-Myb genotype 
and the other breast cancer subtypes (luminal B, HER2+/ER- and unclassified: data not 
shown).  Odds ratios were similar in African-Americans and Caucasians (likelihood-ratio 
tests/LRTs for interaction with race were not statistically significant).  Among controls in the 
CBCS, allele frequencies for the B-Myb G allele were higher in African-Americans (0.27) 
than Caucasians (0.08).   
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Table 2.2.  B-Myb variant genotype (G/G) increases the risk of basal-like breast cancer. 
Abbreviations: A, wild-type; G, variant; OR, odds ratio.  Odds ratios for the B-Myb 
genotype, and basal-like, luminal A and all breast cancer cases.  Patient saples were 
genotyped for the B-Myb polymorphism at codon 427, rs2070235. 
 aAdjusted for offsets, age and race. 
 
 
 
Ectopic Expression of B-Myb Increases Sensitivity to TOP2A Inhibitors.  Given B-Myb’s 
expression within the proliferation signature, evidence suggesting that rapidly growing 
tumors may be more chemotherapy sensitive, and the correlation between B-Myb expression 
and pathological complete response, we sought to determine if ectopic expression of B-Myb 
in vitro had an effect on sensitivity to chemotherapeutics.  B-Myb, and the B-Myb S427G 
variant, were overexpressed in two hTERT-immortalized human mammary epithelial cell 
lines (HME-CC, ME16C) and two basal-like tumor derived lines (SUM102, SUM149) 
(Figure 2.4).  Low endogenous B-Myb levels were detectable by western blot in the tumor 
lines, and in all lines by microarray analysis for mRNA levels (Figure 2.4 and data not 
shown).  All cell lines were also genotyped for rs2070235 and identified as homozygous for 
the major allele.  It is important to note that the two normal tissue derived cell lines have a 
basal-like phenotype when assessed by gene expression analysis (Troester et al., 2004), thus, 
these lines represent appropriate counterparts to the two basal-like tumor lines.  
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Figure 2.4.  Western blot analysis of ectopic expression of B-Myb or B-Myb variant in 
basal-like mammary cell lines.  Two hTERT-immortalized HMEC lines (HME-CC and 
ME16C), and two basal-like tumor derived lines (SUM102 and SUM149) were transduced 
with an empty vector control (C) or B-Myb (M) cDNA expression construct. For one cell 
line (HME-CC), the B-Myb S427G variant (G) was also introduced and analyzed by 
immunoblotting.  To visualize any detectable endogenous B-Myb protein, the B-Myb blot 
was overexposed (“B-Myb Overexposed”; >30 minutes). 
 
Cells ectopically expressing B-Myb, or S427G variant, were treated with a panel of 
chemotherapy agents including two DNA topoisomerase IIα (TOP2A) inhibitors 
(doxorubicin, etoposide), a DNA topoisomerase I inhibitor (camptothecin), a microtubule 
stabilizer (paclitaxel), a DNA alkylating agent (carboplatin), and an antimetabolite (5-
flurouracil), most of which are commonly used in breast cancer treatment.  HME-CC cells 
overexpressing B-Myb, or variant, were approximately twice as sensitive to the two DNA 
topoisomerase IIα inhibitors, based on IC50 assays, compared to the parental cell lines, but 
showed no significant change in sensitivity to the other drugs (Figure 2.5A).  To further test 
B-Myb effects on chemotherapy sensitivity, another immortalized HMEC line (ME16C) and 
two basal-like tumor derived cell lines (SUM102, SUM149) were tested.  The ME16C cell 
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line was also sensitized to TOP2A inhibitors by B-Myb expression, but not to treatment with 
other chemotherapeutics (Figure 2.5B and data not shown); however, this sensitivity profile 
was not observed in either of the two basal-like tumor derived lines (Figures 2.5C and D), 
where B-Myb expression had no apparent effect.  The B-Myb S427G variant was also tested 
in each cell line for chemosensitivity and behaved similarly to the cells overexpressing wild-
type B-Myb (Figure 2.5A and data not shown). 
 
Gene Expression Analysis of Cell Lines Ectopically Expressing B-Myb.  To look for gene 
expression changes in cells overexpressing B-Myb, and to further assess the chemotherapy 
phenotype, microarrays were performed on the HME-CC cell lines.  Under normal, non-
confluent conditions, the only statistically significant expression difference (Significance 
Analysis of Microarrays/SAM analysis (Tusher et al., 2001) with a 3% false discovery 
rate/FDR) was B-Myb itself; also, no gene expression differences were observed between the 
B-Myb and B-Myb S427G-expressing cell lines.  Since a chemotherapy-related phenotype 
was observed with TOP2A inhibitors, we tested the cell lines after treatment with the 72 hour 
IC50 dose of doxorubicin.  In a two-class SAM analysis (i.e. doxorubicin-treated HME-CC 
control vs. doxorubicin-treated HME-CC+B-Myb), 217 genes were identified (FDR <3%; 
Appendix II).    
An EASE (Expression Analysis Systematic Explorer) analysis (Hosack et al., 2003) 
was performed and many cell cycle related gene ontology categories were identified as being 
significantly enriched (Table 2.3).  Therefore, in doxorubicin treated cells overexpressing B-
Myb there was significantly higher expression of many cell cycle genes compared to the 
treated control.   
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Figure 2.5.  Drug sensitivities in B-Myb overexpressing cell lines.  IC50 doses (72h) of 
chemotherapy on cell lines stably expressing vector control, B-Myb, or B-Myb S427G 
variant.  Each MTT experiment was performed in triplicate and error bars represent 95% 
confidence intervals (*p<0.001 relative to vector control).  (A) hTERT-immortalized 
HMEC line HME-CC.  (B) hTERT-immortalized HMEC line ME16C.  (C) Basal-like 
tumor derived cell line SUM102 and (D) SUM149.    
41 
 
 B-Myb is thought to be a transcriptional regulator of G2/M genes (Zhu et al., 2004).  
To determine if the 217-gene SAM list was enriched for genes within a particular phase of 
the cell cycle, each gene was assigned to a specific phase by comparing them to a known list 
derived from a precise cell cycle microarray time course experiment (Whitfield et al., 2002), 
or by literature search.  Out of 217 significant genes, 101 genes were identified as being 
specifically induced during the cell cycle and 60/101 genes were assigned as G2/M-specific 
genes (Figure 2.6).  In addition, previous known B-Myb target genes were present on the 
SAM list including CDC2, Cyclin B1, BIRC5, and the B-Myb binding partner, LIN-9.  
 
 
Table 2.3.  Top 15 significant gene ontology categories determined by EASE 
analysis for B-Myb associated genes.     
 
Abbreviations: EASE, Expression Analysis Systematic Explorer.  Significant 
genes, as determined by SAM, for doxorubicin-treated B-Myb overexpressing 
HME-CC cells versus doxorubicin-treated controls were input to EASE and 
analyzed for enriched gene ontology categories. 
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Figure 2.6.  Enrichment of G2/M phase genes in doxorubicin-treated B-Myb 
overexpressing HME-CC cells.  Significance Analysis of Microarray was used to 
identify 217 significant genes whose high expression was present in B-Myb 
overexpressing cells. These genes were then assigned to a specific phase of the cell 
cycle by comparing them to Whitfield et al., 2002, which identified 101/217 genes as 
being specifically induced during the cell cycle.  The graph shows to which phase of 
the cell cycle these 101 genes mapped.  
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Cell Cycle Profiles of B-Myb Overexpressing Cells.  Since B-Myb expressing, doxorubicin 
treated cells produced a significant G2/M-enriched gene list, we hypothesized that the cell 
cycle profiles of these cells may be different than treated controls.  B-Myb expressing HME-
CC and empty vector controls were both treated with a range of doxorubicin doses for 48 
hours and their cell cycle profiles analyzed for DNA content using flow cytometry.  At zero 
dose or high dose of doxorubicin, the cell cycle profiles for both B-Myb overexpressing cells 
and controls were identical in terms of the percentage of cells in G1 and G2/M phase (Figure 
2.7).  However, at low and intermediate concentrations (10-35 nM) of doxorubicin there was 
a significant difference in the number of cells in G1 or G2/M with a larger percentage of B-
Myb overexpressing cells in G1 versus controls, and a lower percentage of B-Myb 
overexpressing cells in G2/M (Figure 2.7A and 2.7B, respectively); very similar results were 
obtained with etoposide treatment (Figure 2.8).  At high doses of doxorubicin or etoposide, 
regardless of B-Myb expression, the majority of cells arrested in G2/M. 
 
DISCUSSION 
Clinically defined as ER-, PR-, and HER2 not amplified, the basal-like subtype of 
breast cancer portends a poor prognosis.  Basal-like breast cancer has an inherently high 
proliferation rate, which by microarray is identified by high expression of the “proliferation 
signature” genes; this signature has been identified in many publications, in many tumor 
types, and is highly enriched for cell cycle regulated genes (Whitfield et al., 2006).  Here, we 
find that B-Myb, a gene highly expressed within the proliferation cluster, plays an important 
role in regulating cell cycle progression, which likely has effects on patient prognosis and 
response to chemotherapy.  
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Figure 2.7.  Cell cycle profile of HME-CC cells stably expressing B-Myb and treated 
with doxorubicin.  Cell cultures were treated with a range of doses of doxorubicin for 48 
hours followed by propidium iodide DNA content analysis.  Percentage of cells in (A) G1 
phase and (B) G2/M were calculated by gating based on DNA content.  Error bars indicate 
standard deviations between three independent experiments. 
 
 
 
Figure 2.8.  Cell cycle profile of HME-CC cells stably expressing B-Myb and treated 
with etoposide.  Cell cultures were treated with a range of doses of etoposide for 48 hours 
followed by propidium iodide DNA content analysis.  Percentage of cells in (A) G1 phase 
and (B) G2/M were calculated by gating based on DNA content. Error bars indicate 
standard deviations between three independent experiments.  
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We showed that B-Myb high expression was significantly associated with the poor 
outcome, basal-like breast cancer subtype and that B-Myb gene expression levels alone 
predicted poor outcomes in the absence of therapy  (i.e. prognosis, Figure 2.2) and are 
correlated with achieving a pCR (i.e. prediction, Table 2.1).  Stratification of B-Myb 
expression, even within the luminal A, B, and HER2+/ER- subtypes, or ER+ tumors, was 
significantly associated with survival.  Stratification of B-Myb expression within basal-like 
tumors did not predict outcomes, nor was outcome predicted in the ER- subset of the Wang 
et al., 2005 dataset (which includes basal-like tumors); however, these are inherently poor 
outcome tumors that significantly trend towards high B-Myb expression (Figure 2.3). 
The B-Myb chromosomal locus, 20q13, is found amplified in a variety of cancers, 
including breast (Chin et al., 2006), and this amplification is linked to poor prognosis 
(Bergamaschi et al., 2006).  Gene copy number analysis across breast tumor subtypes 
suggested that the genomic amplification of B-Myb was not enriched in the basal-like 
subtype, but instead was enriched in the luminal B subtype (Bergamaschi et al., 2006).  
Therefore, within luminal tumors, B-Myb amplification and expression is an event that 
appears to be selected for and portends a poor prognosis (Figures 2.2B, C).  In basal-like 
tumors the high expression of B-Myb may be due to other regulatory mechanisms, possibly 
by virtue of their inherently high proliferation rates, by amplification of transcription 
factor(s) targeting B-Myb, or by selectively enhanced promoter activity.  This dual behavior 
of basal-like tumors, a subtype typical of chemo-responsiveness but with poor patient 
outcomes, has been described before and termed the “basal-like tumor paradox” (Carey et al., 
2006), and the data presented here suggest that B-Myb may be a key regulator of this 
complex phenotype. 
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Recently, Schwab et al. 2007, linked the nonsynonymous B-Myb germline variant 
(S427G, rs2070235) to a decrease in overall cancer risk when combining neuroblastomas, 
chronic myelogenous leukemia, and colon cancers into a single dataset and comparing this 
grouping of cases to non-cancer bearing controls.  While both studies are technically accurate 
(i.e. similar allele frequencies in the control populations; CBCS: homozygous major allele 
72.6%, heterozygous 24%, homozygous minor allele 3.4%; Schwab et al., 2007: 72.1%, 
27.3%, and 0.4%, respectively), the association of B-Myb rs2070235 genotype and basal-like 
breast cancer susceptibility differs from the previous report and has not been described 
before.  Here, in a population based case-control study, we found that the rs2070235 minor 
allele was associated with increased risk of basal-like breast cancer but not other subtypes in 
the CBCS (Table 2.2).  The discrepancy between the Schwab data and what is reported here 
may be due to differences between breast cancer and the cancers examined in the Schwab 
paper.  Even amongst breast cancers there is significant heterogeneity across the subtypes in 
terms of the etiologic role of the B-Myb allele, and an analysis of breast cancer without 
subdivision would have missed the association of rs2070235 with the basal-like breast cancer 
subtype.   
Presently, the function of the S427G variant is unknown.  Our in vitro studies in 
breast epithelial cell lines showed neither a phenotypic difference between the 
overexpression of B-Myb or its variant on chemosensitivity relative to each other, nor did we 
observe a difference in their baseline gene expression patterns. It is tempting to speculate that 
rs2070235 has functional consequences and somehow contributes to the etiology of basal-
like tumors.  The B-Myb variant was found to be nearly ten-fold more frequent in African-
Americans (7%) versus non-African-Americans (0.8%) in the CBCS.  This is relevant in 
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light of recent data showing that premenopausal African-Americans are approximately twice 
as likely to develop basal-like tumors compared with premenopausal Caucasians (Carey et 
al., 2006; Millikan et al., 2008).  Of note, Schwab et al., 2007 demonstrated that the B-Myb 
S427G protein was more stable than the wild-type protein.  This increased stability may 
correspond to elevated B-Myb protein levels, possibly increasing transcriptional activity of 
G2/M cell cycle genes and leading to higher inherent proliferation rates.  This alteration of 
cell cycle control may contribute to B-Myb’s influence on poor outcome breast cancers.  
Additional assays are required to more fully investigate the role of rs2070235 and other 
variants in B-Myb that may also lie in linkage disequilibrium with the G allele.  This is an 
important area of investigation, since it is possible that one or more variants in B-Myb could 
contribute to the higher frequency of basal-like breast cancer among African-American 
breast cancer patients and may contribute to the pathophysiology of basal-like breast cancer. 
Since chemotherapy is currently the only option for basal-like patients, we explored if 
increased B-Myb expression had any effect on chemosensitivity in vitro.  We observed a 
statistically significant increase in sensitivity to two TOP2A inhibitors, doxorubicin and 
etoposide, in the HME-CC and ME16C cells overexpressing B-Myb or its variant, but this 
phenotype was not observed in the basal-like tumor derived cell lines (Figure 2.5).  Also, 
there was no significant difference in chemosensitivity to the other tested drugs in any of the 
cell lines, which included camptothecin, a DNA topoisomerase I (TOP1) inhibitor.  TOP2A, 
a nuclear enzyme that relaxes both negative and positive DNA supercoils by creating double-
stranded DNA breaks, is of particular importance for proper DNA duplication during S-phase 
of the cell cycle (Smith et al., 1994).  TOP2A inhibitors cause the enzyme to become trapped 
on double-strand DNA breakpoints, thereby causing G2 cell cycle checkpoint arrest.  Since 
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B-Myb is a G2/M regulating gene, increased B-Myb expression may be promoting the 
TOP2A-inhibitor treated cells through the G2 checkpoint via induction of downstream B-
Myb target genes.  By facilitating cells through G2, with less regard for DNA damage, the B-
Myb overexpressing cells may attempt to cycle again, eventually leading to the increased 
sensitivity to TOP2A phenotype observed; see hypothetical model (Figure 2.9).  TOP2A 
itself was on the B-Myb induced gene list (Supplementary Table 2) and thus more of the 
target of doxorubicin and etoposide was present, adding to the observed sensitivity 
phenotype in B-Myb overexpressing cells.     
In support of this hypothesis, the gene list identified by microarray analysis as being 
highly expressed in doxorubicin-treated, B-Myb overexpressing cells (Appendix II) was 
significantly enriched in genes required for G2/M progression.  For example, this list 
included the newly described B-Myb interacting protein LIN-9, a protein required along with 
B-Myb for the transcription of G2/M genes (Osterloh et al., 2007).  In addition, our B-Myb 
target gene list contained many previously identified B-Myb targets including CDC2, 
CyclinB1, and BIRC5 (Osterloh et al., 2007; Zhu et al., 2004).  This gene list represents 
putative mammary B-Myb target genes and again suggests that B-Myb has its greatest effect 
on G2/M genes.  In agreement with the gene list enrichment results, when B-Myb 
overexpressing cells were treated with low doses of doxorubicin or etoposide, more cells 
accumulated in G1 versus controls, suggesting that the control cell line was appropriately 
inhibiting cell cycle progression at G2, whereas B-Myb overexpressing lines were bypassing 
this checkpoint (Figures 2.7 and 2.8).     
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Figure 2.9
  
50 
 
 
 
 
 
 
 
 
 
Figure 2.9.  B-Myb expression may increase anti-proliferative effects of TOP2A 
inhibitors.  Hypothetical model depicting HME-CC cells treated with TOP2A inhibitor (A) 
expressing endogenous B-Myb levels or (B) B-Myb overexpression.  
51 
 
The results of this study enhance our understanding of the role of B-Myb in breast 
cancer by identifying new B-Myb target genes, by showing that this gene is highly expressed 
in basal-like breast cancers, and by showing it is of prognostic value for survival and 
predictive value for pathological complete response.  Also, we have described a significant 
correlation between a B-Myb variant and an increased risk of basal-like breast cancer.  These 
findings point to B-Myb as a biomarker that is of potential clinical importance for 
determining disease risk and for guiding treatment.  In addition to its role in basal-like 
cancers, B-Myb may also be of great importance in luminal tumors, a breast cancer subtype 
with relatively good prognosis, since B-Myb expression was capable of stratifying the poor 
from the good actors within this group, and it is within this group where B-Myb is 
occasionally amplified on the DNA level.  The link between B-Myb high expression and 
increased chemotherapy sensitivity in vitro is mirrored by similar findings in vivo where we 
and others have shown that basal-like tumors are, on average, the most sensitive to multi-
agent chemotherapy regimens that contain an anthracycline (Carey et al., 2007; Rouzier et 
al., 2005).  It is unlikely that B-Myb expression alone is responsible for the chemotherapy 
sensitivity of basal-like tumors, but when coupled with the loss of TP53 function, which is 
known to occur in basal-like tumors (Sorlie et al., 2001), and the loss of RB function 
(Derenzini et al., 2008; Herschkowitz et al., 2008), multiple important checkpoints are 
deficient in basal-like tumors and it is this lack of control that may ultimately prove to be 
their Achilles’ heel. 
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CHAPTER III 
TUMOR SUPPRESSOR ROLE FOR THE C-MYB ONCOGENE IN  
LUMINAL BREAST CANCER 
 
PREFACE 
 This chapter represents the results described in two manuscripts.  The first 
manuscript, describing the role of c-Myb in luminal breast cancer, is in the submission 
process.  My role in this project included initiating, organizing, and designing the study.  I 
performed the microarray data analysis, c-Myb knock-down in mammary cell lines, 
chemotherapy treatment, and both in vitro and in vivo tumorigenicity experiments.  I initiated 
all aspects of manuscript preparation, including writing, figure preparation, and revisions.  
Katherine A. Hoadley aided in study design and contributed writing of the manuscript.  Joel 
S. Parker assisted with microarray statistical analysis.  Charles M. Perou was the principal 
investigator, conceived the project, and contributed to writing the manuscript. 
 
Thorner AR, Parker J, Hoadley KA, Perou CM.  Tumor suppressor role for the c-Myb 
oncogene in luminal breast cancer. (Manuscript in preparation) 
 
The second manuscript, examining the role of c-Myb in p53 stabilization, is currently 
under review at Molecular and Cellular Biology.  Chad Deisenroth and principal investigator 
Yanping Zhang carried out experiments describing the interaction between Hep27 and p53.  I 
performed all microarray analysis and c-Myb knock-down experiments.   
Deisenroth C, Thorner AR, Enomoto T, Perou CM, and Zhang, Y. Mitochondrial Hep27 is a 
c-Myb target gene that inhibits Mdm2 and stabilizes p53. (Submitted to MCB, 2009) 
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ABSTRACT 
 The transcription factor c-Myb has been well characterized as an oncogene in several 
human tumor types, and its expression in the hematopoietic stem/progenitor cell population 
is essential for proper hematopoiesis.  However, the role of c-Myb in mammopoeisis and 
breast tumorigenesis is poorly understood, despite its high expression in the majority of 
breast cancer cases (60-80%).  We find that c-Myb high expression in human breast tumors 
correlates with the luminal/ER+ phenotype and a good prognosis. RNAi knock-down of 
endogenous c-Myb levels in the MCF7 luminal breast tumor cell line increases tumorigenesis 
both in vitro and in vivo, suggesting a tumor suppressor role in luminal breast cancer.  We 
created a mammary-derived c-Myb expression signature and found it highly correlated with a 
published mature luminal mammary cell signature and least correlated with a mammary 
stem/progenitor lineage gene signature.  These data describe, for the first time, a tumor 
suppressor role for the c-Myb proto-oncogene in breast cancer that has implications for 
understanding luminal tumorigenesis and for guiding treatment.  
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INTRODUCTION 
 Breast cancer is a heterogeneous disease and numerous studies have defined at least 
five molecular subtypes of breast tumors using an “intrinsic” gene set (Hu et al., 2006; 
Parker et al., 2009; Perou et al., 2000).  The luminal/estrogen receptor alpha positive (ER+) 
subtypes are the most commonly diagnosed breast cancer (60-80 percent), with patients 
being classified as either good outcome Luminal A, or poor outcome Luminal B.  Patients 
with Luminal A tumors have good overall survival, in part, because these tumors are slow 
growing, often respond to selective estrogen receptor modulators, and have infrequent TP53 
mutations (Riggs and Hartmann, 2003; Sorlie et al., 2001).  The luminal subtypes are defined 
by high expression of approximately 80 genes within the intrinsic gene list, including ERα, 
GATA3, FOXA1, and c-Myb, the latter of which is a known proto-oncogene frequently 
observed as amplified in a variety of tumor types (Oh and Reddy, 1999). 
 Nearly three decades ago the c-Myb transcription factor was identified as the 
mammalian homolog of v-myb, a transforming retroviral oncogene linked to avian leukemia 
(Klempnauer et al., 1982; Leprince et al., 1983).  Since that time, c-Myb high expression has 
been associated with oncogenic activity and poor prognosis in several human cancers 
including T-cell leukemia, acute myelogenous leukemia, colorectal tumors, and most 
recently in adenoid cystic carcinomas (Biroccio et al., 2001; Oh and Reddy, 1999; Persson et 
al., 2009).  In addition, c-Myb has been implicated in progenitor cell maintenance and is 
required for proper cellular differentiation in the hematopoietic system, neuronal cells, skin 
cells, and colonic crypts (Kopecki Z, 2007; Malaterre et al., 2007; Malaterre et al., 2008; 
Mucenski et al., 1991).  c-Myb high expression is frequently associated with a variety of 
immature cell lineages, and expression levels decrease as cells differentiate (Ess, 1999).  
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However, there has been very little discovered about the role of c-Myb in normal 
mammopoeisis and breast tumorigenesis, despite its high expression in virtually all ER+ 
tumors as well as in 29% of hereditary and typically ER-negative BRCA1 breast cancers 
(Guérin M, 1990; Kauraniemi et al., 2000). 
 To gain insight into c-Myb and its involvement in breast cancer, we analyzed the 
expression of c-Myb in the context of breast tumor subtypes, and examined its association 
with patient outcomes.  We also manipulated the expression of c-Myb via RNA interference 
in a luminal/ER+ mammary cell line, observed alterations in growth properties both in vitro 
and in vivo, and identified a mammary-specific c-Myb gene signature. 
 
MATERIALS AND METHODS 
Cell Culture.  c-Myb knock-down.  MCF7 cells (a gift from F. Tamanoi, University of 
California-Los Angeles, Los Angeles, CA) were maintained in RPMI-1640 plus 10% FBS at 
37C and 5% CO2.  Stable knock-down of c-Myb in MCF7 cells was accomplished using a 
short hairpin RNA against c-Myb (shMYB; 
CGTTGGTCTGTTATTGCCAAGCACTTAAA) and compared to a knock-down control 
(shGFP) cloned into the pRS vector, purchased from OriGene (Catalog No. TR311329).  
Retrovial transduction was performed as described (Thorner et al., 2009).  Stable populations 
were selected by culturing in 2 ug/mL puromycin for two weeks.  Cells were then plated at 
clonal density and >20 colonies screened by western blotting as described (Thorner et al., 
2009) for c-Myb (Abcam, ab45150), and β-tubulin (Santa Cruz, sc-9104).  The clones with 
greatest knock-down were expanded for further analyses. 
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Addition of ZsGreen1.  PT67 cells stably expressing retrovirus containing 
pLNCX2_ZsGreen1 (a generous gift from Dr. Kathryn B. Horwitz at the University of 
Colorado Health Sciences Center, Aurora, Colorado) were propagated as described (Harrell 
et al., 2006).  MCF7 cells stably expressing shMYB or shGFP were transduced, as described 
above, with pLNCX2_ZsGreen1-containing retrovirus and kept under constant selection 
using 400 ug/mL G418. 
 
In Vitro Analyses.  Doubling Time Assay.  MCF7 cells stably expressing shMYB or shGFP 
were seeded, in duplicate, into 10 centimeter dishes at 50,000 cells per plate.  Cells were 
allowed 48 hours of growth prior to the first counting (t=0), followed by counting at 48, 72, 
and 124 hours (Beckman Z1 Coulter Particle Counter).  Doubling times were estimated by 
linear regression.  
Colony Formation Assay.  Soft agar assays were performed in triplicate in six-well ultra-low 
attachment plates (Corning).  Briefly, a medium-agar mix was prepared by combining 2x 
RPMI-1640 (Invitrogen, 23400-021), 5.6 mL 1x RPMI (Invitrogen), 2.4 mL FBS (Sigma), 
and 8 mL 1.8% Noble agar (Sigma, A5431-250G).  A volume of 2.3 mL of the medium-agar 
mix was added to each well, to create a bottom layer, and allowed to solidify.  MCF7 cells 
(shMYB or shGFP) were washed with PBS, trypsinized, counted, and 8,000 cells were 
combined with 3 mL of medium-agar mix to create the top agar layer in each well.  Once the 
top agar layer solidified, 0.5 mL of selective media (RPMI-1640, 10% FBS, 2 ug/mL 
puromycin) was added to each well and changed with fresh media every three days.  Cells 
were grown for 15-20 days until colonies were visible.  Colonies were visualized by 
removing liquid media, adding 200 microliters of  MTT dye (Cell-Titer 96, Promega 
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#G4100), incubating for one hour at 37 C, followed by scanning the plates and manual 
counting of colonies.  Statistical significance was calculated using a two-tailed t-test. 
MTT Assay.  To estimate the IC50 of tamoxifen (Sigma-Aldrich #T9262) on cell lines, a 
modified MTT assay was performed as previously described (Thorner et al., 2009). 
 
In Vivo Tumor Analysis.  MCF7 cells stably expressing shMYB+ZsGreen1 or 
shGFP+ZsGreen1 were collected, counted, and 550,000 cells, embedded in Matrigel, were 
injected into each fourth mammary gland of Nude mice (Harlan Laboratories, Hsd:Athymic 
Nude-Foxn1nu).  Tumors were allowed to grow for 15 weeks then measured by caliper.  Each 
tumor area was calculated and statistical significance between the means of experimental 
versus control determined using a one-tailed independent t-test. 
 
Microarray Analysis.  Poly-A(+) RNA was collected (Micro-FastTrack2.0 mRNA Isolation 
Kit, Invitrogen) from six replicates of MCF7 cells stably expressing shGFP and five 
replicates expressing shMYB, reverse transcribed and labeled using the Agilent Low RNA 
Input Linear Amplification Kit (Agilent Technologies, Santa Clara, CA, USA), and 
hybridized to Agilent Human 4x44K Custom Oligo microarrays, adapted from 
manufacturer’s protocol.  An untreated MCF7 cell line reference was co-hybridized to each 
array.  Microarrays were scanned on an Agilent Technologies DNA Microarray Scanner with 
Surescan High-Resolution Technology (Part no. G2565CA) and the image analyzed using 
Agilent Feature Extraction Software.  Data was normalized using Lowess normalization on 
the Cy3 and Cy5 channels.  Microarray data is available at the UNC Microarray Database 
[http://genome.unc.edu] and will be available at the Gene Expression Omnibus. 
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Microarray Statistical Analyses.  Supervised microarray analysis was performed on the 
MCF7-c-MYB RNAi vs. MCF7-vector control by selecting genes with an absolute signal 
intensity of at least 10 units in both dye channels and data present in at least 70% of 
experimental samples.  A two-class, unpaired Significance Analysis of Microarrays (SAM) 
was performed to identify significant genes associated with c-Myb knock-down with a false 
discovery rate (FDR) of less than 5% (Tusher et al., 2001). 
 Breast tumor microarray data on tumors without adjuvant chemotherapy (local-only 
Tx; n=145) from the Netherlands Cancer Institute (van de Vijver et al., 2002) was used to 
analyze both c-Myb’s relation to survival and its expression across breast cancer subtypes.  
Gene expression levels of c-Myb were rank ordered, split into halves (high-to-low) and 
relation to survival tested using the chi-square test and visualized by Kaplan-Meier survival 
plots (WinSTAT v.2007.1).  Testing the association of c-Myb expression versus subtypes 
was performed by ANOVA using the R system for statistical computing (R Development 
Core Team, 2006 http://www.R-project.org). 
 
Other Statistical Analyses.  To test the relation of the c-Myb, GATA3, and ER gene 
signatures to mammary cell lineage gene signatures, cell line models were used to 
characterize the different signatures.  In each experiment, microarray data provides a 
signature of the activity for further evaluation. The gene signatures used in this experiment 
include c-Myb signature described above, a GATA3-signature from Usary et al. (Usary et al., 
2004), and an ER-signature from Oh et al. (Oh et al., 2006); each of these three signatures 
were compared to the mammary cell lineage gene signatures previously defined (Lim et al., 
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2009).  Signatures were defined by the SAM statistics corresponding to differentially 
expressed genes (FDR< 5%) from the model comparison, and these SAM statistics were used 
to weight each gene.  Tumor (UNC-324 breast tumor dataset; GSE10893) and mammary cell 
lineage samples were evaluated by calculating the inner product of the signature gene 
weights and the sample.  The resulting value is a relative activity measure of the signature.  
Boxplots were generated to relate the activity measure of each signature across tumor 
subtypes and sorted mammary cell lines. 
 
RESULTS 
c-Myb High Expression Correlates with Good Prognosis.  To study the role of c-Myb in 
breast tumors, we first examined whether associations between c-Myb mRNA expression and 
patient outcomes exists. The Netherlands Cancer Institute locally-treated (no adjuvant 
chemotherapy) breast tumor microarray dataset (NKI-295, local-only Tx: n=145; (van de 
Vijver et al., 2002) was classified into the intrinsic subtypes (Luminal A, Luminal B, HER2-
enriched, Basal-like, and Normal-like) using the PAM50 classifier, as described (Parker et 
al., 2009).  An ANOVA was performed to determine statistical significance of c-Myb 
expression across the breast cancer subtypes (Figure 3.1A).  Expression of c-Myb differed 
significantly across the subtypes with highest expression observed in the ER+, Luminal A 
and B subtypes and lowest expression in the Basal-like/ER- tumors.  High c-Myb expression 
levels were also significantly correlated with smaller tumor size and lower grade (Figures 
3.1B and C).  Similar results were observed using two other published microarray datasets 
(data not shown) (Herschkowitz et al., 2007; Miller et al., 2005). 
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Figure 3.1.  c-Myb high expression correlates with luminal breast cancer, small tumor 
size and low tumor grade. NKI local-only treated tumor dataset (n=145) was tested for (A) 
c-Myb expression across breast tumor subtypes. Statistical significance calculated by 
ANOVA.  This same dataset was tested for the relationship of c-Myb gene expression to (B) 
tumor size or (C) tumor grade.  Statistical significance determined by t-test or ANOVA. 
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 Using this same NKI=145 cases dataset, we tested if c-Myb expression levels 
correlated with patient outcomes.  Tumors were rank ordered (low-to-high) based on c-Myb 
mRNA expression levels and were analyzed for overall survival (OS) using Kaplan-Meier 
analysis in all tumors, as well as within each subtype.  High c-Myb expression levels 
significantly correlated with better survival across all subtypes (Figure 3.2A; n=145), as well 
as in the combined Luminal A+B subtypes (Figure 3.2B; n=87), but not in the HER2-
enriched or Basal-like subtypes (Figures 3.2C and D). 
 We also investigated if c-Myb expression levels correlate with achieving a 
pathological complete response (pCR).  Using published data (Hess et al., 2006) consisting 
of microarrays on breast tumors of patients receiving neoadjuvant paclitaxel, and subsequent 
5FU-Adriamycin-Cyclophosphamide (T/FAC; n=133), we observed that high c-Myb levels 
significantly correlated with a poor pCR (Table 3.1); this finding is consistent with previous 
findings that high ER levels predict poor pCR rates (Hess et al., 2006).  
 
Table 3.1.  Pathologic complete response, pCR, data of Hess et al., (2006) rank ordered, split 
into halves (high/low) based on c-Myb expression values, and analyzed by chi-square. 
 
 
c-Myb Knock-down in MCF7 Cells Increases Tumorigenesis in vitro and in vivo.  Based 
on our observations that higher levels of c-Myb are predictive of good outcomes in all breast 
tumors, as well as in luminal tumors, we utilized RNA interference (short hairpin RNA: 
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shRNA) to knock-down endogenous c-Myb protein in the luminal tumor-derived cell line, 
MCF7 (Figure 3.3A).  Microarray analysis revealed that transcript levels of c-Myb were 
decreased 2.5-fold relative to the control (data not shown), while western blot analysis 
showed little to no c-Myb protein expression.  A cell proliferation assay was performed to 
compare the doubling time of MCF7 cells with the stable c-Myb knock-down (shMYB) 
versus control (shGFP) (Figure 3.3A).  Cells with c-Myb knock-down grew faster in vitro 
(Figure 3.3B).   
 Furthermore, both cell lines were tested for anchorage-independent growth by means 
of colony formation in soft agar with MCF7 cells having depleted c-Myb protein able to form 
nearly 14-fold more colonies than controls (Figures 3.3C and D).  We assayed both cell lines 
for their relative sensitivities to tamoxifen and found that MCF7 cells with reduced c-Myb 
levels were more resistant to tamoxifen based on IC50 estimates (Table 3.2).  
 
 
 
Table 3.2.  IC50 doses (72h) of tamoxifen on c-Myb 
knock-down (shMYB) versus control (shGFP).   
 
Tamoxifen IC50 Std Dev
shGFP 6.5 6.2-6.9
shMYB 7.9 7.0-8.9
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Figure 3.2.  c-Myb high expression correlates with good prognosis in all breast subtypes 
combined and luminal tumors.  Kaplan-Meier overall survival (OS) analysis based on c-
Myb expression values rank ordered into halves (high-to-low): (A) All subtypes combined 
(n=145, local-only treatment (Tx)), (B) Luminal A and B subtypes only (n=87), (C) Basal-
like (n=28) and (D) HER2+ (n=30).  
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Figure 3.3. 
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Figure 3.3.  c-Myb knock-down increases luminal tumor growth both in vitro and in 
vivo.  (A) Western blot analysis of c-Myb knock-down (shMYB) versus control (shGFP) in 
MCF7 cells.  (B) Doubling times calculated by linear regression.  CI: confidence interval (C) 
Representative dishes displaying the effects of c-Myb knock-down in a soft agar colony 
formation assay.  (D) Quantification of colony formation assay.  Statistical significance 
determined by two-tailed independent t-test.  (E) Tumor area of nude mice fifteen weeks 
after injection of MCF7 shGFP or shMYB; representative images were taken of each tumor 
type in live mice.  Error bars represent standard error and p-value calculated by a two-tailed 
independent t-test. 
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 To examine if the in vitro data were relevant in in vivo xenografts, we stably 
expressed ZsGreen1, a reef coral fluorescent protein, in both of the MCF7 cell lines (shMYB 
and shGFP) to allow for ease of in vivo tumor visualization.  Nude mice (without estrogen 
pellets) were injected with 5.5x105 cells that were embedded in Matrigel into each fourth 
mammary gland (shGFP, n=10; shMYB, n=9).  Fifteen weeks post-injection representative 
images were taken of tumors in live mice, and tumor area calculated.  Tumors containing the 
c-Myb knock-down line were significantly larger than controls (Figure 3.3E, p=0.02). 
 
c-Myb Expression Signature Identifies Many Luminal/ER+ Subtype Defining Genes.  In 
order to identify the transcriptional targets of c-Myb in breast cells, Agilent microarrays were 
used to assess gene expression differences between MCF7 shMYB (n=5) versus MCF7 
shGFP (n=6).  In a two-class Significance Analysis of Microarrays (SAM) analysis (Tusher 
et al., 2001), 1,211 significantly differentially expressed genes were identified using a false 
discovery rate (FDR) of less than 5% (data not shown), henceforth termed the “c-Myb gene 
signature”.  Several previously identified c-Myb target genes were on this list including KIT, 
DHRS2 (Hep27), and EMP2 (Hogg et al., 1997; Lei et al., 2004; Rushton et al., 2003). 
 c-Myb is an estrogen receptor target gene (Gudas et al., 1995), and is repeatedly 
observed as being highly expressed in the luminal “intrinsic” gene set (Oh et al., 2006; Usary 
et al., 2004).  To determine if genes within the c-Myb gene signature overlap with the 
luminal intrinsic gene set, we used the 232 breast tumor microarray data of Herschkowitz et 
al., 2007, clustered the tumors using the ~2000 intrinsic gene list described by Parker et al., 
2009, and defined the luminal cluster as genes highly correlated (0.65 node correlation; 79 
genes total) with ESR1, a central gene in the luminal cluster (Figure 3.4 and Table 3.3).   
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Figure 3.4.  UNC breast tumor microarray dataset (n=232; Herschkowitz et al., 2007) 
clustered using an intrinsic gene set (Parker et al., 2009).  The luminal gene cluster, 
identified as genes highly correlated with the ESR1 gene node (0.65 node correlation; 79 
genes) is displayed on the right.  Dendrogram branches are colored by subtype: luminal A: 
dark blue, luminal B: light blue, basal-like: red, normal-like: green, HER-2 enriched: pink. 
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Table 3.3.  c-Myb, ER, and GATA3 gene signature define many luminal cluster genes.  
Gene names and GenBank accession numbers of the 79 genes highly correlated with the ESR1 
gene node (0.65 node correlation).  Overlapping genes with c-Myb-, GATA3- and ER-gene 
signatures are listed. 
GenBank Accession Number Luminal Cluster-Defining Genes Signature Overlap 
NM_030627 CPEB4 c-Myb 
NM_003479 PTP4A2 ER 
NM_017423 GALNT7 
 NM_006379 SEMA3C 
 NM_004694 SLC16A6 
 NM_004374 COX6C c-Myb 
NM_175605 TTC10 
 NM_006460 HIS1 
 NM_015541 LRIG1 c-Myb 
NM_000633 BCL2 
 NM_019000 FLJ20152 c-Myb 
NM_016121 KCTD3 c-Myb 
NM_006996 SLC19A2 
 NM_033211 LOC90355 c-Myb 
NM_006113 VAV3 
 NM_145252 LOC124220 GATA3 
NM_130898 CREB3L4 
 NM_020775 KIAA1324 c-Myb 
AK000820 ZNF587 
 NM_024762 ZNF552 
 NM_144611 MGC32124 
 NM_173075 APBB2 
 NM_016613 DKFZp434L142 c-Myb 
NM_006726 LRBA 
 NM_206927 SYTL2 
 NM_152400 FLJ39370 
 BC071555 IL6ST 
 NM_024863 TCEAL4 
 NM_001012979 
  NM_001006640 TCEAL1 
 NM_014399 TM4SF13 GATA3 
NM_014373 GPR160 GATA3 
NM_080759 DACH1 
 NM_017786 FLJ20366 c-Myb 
NM_012319 SLC39A6 c-Myb 
NM_207446 LOC400451 GATA3 
BC023981 CA12 c-Myb+ER+GATA3 
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GenBank Accession Number Luminal Cluster-Defining Genes Signature Overlap 
NM_003226 TFF3 GATA3 
NM_005080 XBP1 c-Myb+ER+GATA3 
NM_000044 AR c-Myb 
NM_004496 FOXA1 GATA3 
NM_006408 AGR2 c-Myb+GATA3 
NM_176813 BCMP11 
 NM_021800 DNAJC12 
 NM_001002295 GATA3 GATA3 
NM_000125 ESR1 
 NM_024817 FLJ13710 
 NM_014599 MAGED2 
 NM_000507 FBP1 c-Myb 
NM_001002837 PIB5PA 
 NM_020686 ABAT 
 NM_014246 CELSR1 
 NM_005375 MYB c-Myb 
NM_003462 DNALI1 c-Myb 
NM_016569 TBX3 
 NM_020974 SCUBE2 c-Myb 
NM_032309 CHCHD5 
 NM_174921 LOC201895 
 NM_024573 C6orf211 
 NM_001609 ACADSB 
 NM_001001664 LOC339745 
 NM_000015 NAT2 c-Myb 
NM_000662 NAT1 c-Myb 
NM_019600 FLJ10980 
 NM_032780 TMEM25 c-Myb 
NM_003866 INPP4B 
 NM_018379 FLJ11280 
 NM_018000 FLJ10116 ER 
BC028374 C1orf34 GATA3 
NM_007013 WWP1 
 NM_003489 NRIP1 ER 
A_23_P14432 
  NM_014048 MKL2 
 NM_032918 RERG c-Myb+ER 
NM_002513 NME3 
 NM_016463 CXXC5 
 NM_005264 GFRA1 c-Myb 
NM_021814 ELOVL5 c-Myb+ER 
NM_014912 CPEB3 
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We also analyzed previously published ER and GATA3 gene signatures to determine their 
luminal cluster contributions (Oh et al., 2006; Usary et al., 2004).  The c-Myb signature had 
the largest number of genes overlapping with the luminal cluster (24%), followed by GATA3 
(10%) and ER (4%) signature genes, and unique combinations of the signatures accounting 
for 6% (Table 3.3). These data suggest that the Luminal/ER+ cluster is a combination of the 
effects of multiple transcription factors, with c-Myb being a major contributor. 
 
c-Myb Gene Signature Correlates with Mature Luminal Mammary Cell Lineage.  
Recently Lim et al. used florescence activated cell sorting (FACS) of normal, human 
mammary tissue to isolate four discrete cell populations within the mammary gland hierarchy 
(i.e. stromal, mammary stem cell, luminal progenitor, and mature luminal populations) (Lim 
et al., 2009).   Unique gene expression signatures for each of the mammary gland lineages 
were revealed by microarrays, and these signatures compared to our cell line-derived ER, 
GATA3, and c-Myb gene signatures (Figure 3.5, right graphs).  The ER gene signature was 
significantly correlated with both the luminal progenitor and mature luminal populations, 
whereas the GATA3 gene signature was highly correlated with the mature luminal 
population, and to a lesser extent, the luminal progenitor lineage (Figures 3.5A and 3.5B, 
respectively).  The differentiated, mature luminal lineage displayed high c-Myb regulated 
activity that was not observed in the other cell populations, including the mammary stem cell 
population (Figure 3.5C). 
Tumor gene expression profiles were processed in the same fashion as the sorted cell 
lines and tumor profiles were compared to the ER, GATA3, and c-Myb gene signatures to 
demonstrate which breast tumor subtypes were enriched for these signatures (Figure 3.5, left 
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Figure 3.5. 
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Figure 3.5.  c-Myb gene signature correlates with mature (differentiated) luminal 
mammary cells.  (A) ER-, (B) GATA3-, and (C) c-Myb- regulated activities across UNC 
breast tumors (n=324; GSE10893) or mammary gland cell lineage gene signatures (Lim et 
al., 2009).  Tumor gene expression was weighted according to ER, GATA3, or c-Myb gene 
signatures by calculating the inner product of each signature and the tumor expression 
profile.  Lim et al. lineage signatures were processed in the same fashion as tumors to 
demonstrate the developmental context of these signatures.   
MaSC: mammary stem cell-enriched; LP: luminal progenitor; ML: mature luminal; St: 
Stromal.   
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graphs).  The ER gene signature was highest in the luminal A subtype and lowest in the ER-
negative, basal-like tumors (Figure 3.5A).  The GATA3 gene signature was most strongly 
correlated with the HER2-enriched subtype (Figure 3.5B).  The c-Myb gene signature was 
strongly correlated with the Luminal A and HER2-enriched subtypes, and was least 
correlated with basal-like tumors.   
 
 
DISCUSSION 
 
The essential role of the c-Myb oncogene in leukemogenesis has been appreciated for 
several decades.  Its expression is required for maintenance of both acute and chronic 
myeloid leukemia cells (Anfossi, 1989; Calabretta, 1991).  c-Myb is also necessary for 
normal hematopoiesis; knock-out mice succumb to embryonic lethality (e15) due to 
unsuccessful blood cell lineage formation (Mucenski et al., 1991), and lineage-specific 
knockouts have revealed that c-Myb is required for proper T-cell differentiation (Bender et 
al., 2004). Studies in colorectal carcinoma have found high c-Myb expression to correlate 
with poor prognosis (Biroccio et al., 2001), and more recently the fusion of c-Myb and the 
transcription factor NFIB has been reported as a potential “hallmark” of adenoid cystic 
carcinomas (Persson et al., 2009).  Based on these data it has been hypothesized that c-Myb 
is necessary for progenitor cell maintenance, and decreasing c-Myb expression is crucial for 
cellular differentiation (Ramsay and Gonda, 2008). 
Our data in breast tumors, however, suggest a tumor suppressor role for c-MYB 
where high expression portents a good outcome and high differentiation status of tumors.  It 
is known that c-Myb is a direct target of the estrogen receptor alpha (ER), and c-Myb protein 
levels are increased in ER+ tumors (Guérin M, 1990).  Here, our findings confirm that c-Myb 
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high expression correlates with the ER+, Luminal A and B subtypes of breast cancer (Figure 
3.1A). Unlike the other tumor types discussed above, breast tumors having high c-Myb 
expression levels correspond with a good prognosis, even within luminal breast tumors alone 
(Figures 3.1A and B).  We purposefully used a microarray dataset where patients received no 
adjuvant chemotherapy so as not to confound the survival data with the use of 
chemotherapeutics, particularly estrogen antagonists. 
To analyze the role of c-Myb in breast tumorigenesis, we chose to knock-down 
endogenous c-Myb levels in MCF7 cells, which is a luminal breast tumor cell line (Neve et 
al., 2006).  When c-Myb protein levels were significantly decreased relative to the parental 
cell line, we observed faster cell growth, decreased tamoxifen sensitivity, and increased 
colony formation in vitro (Figures 3.3B-D).  These observations were preserved in vivo 
where MCF7 cells, with c-Myb knocked-down, grew significantly faster in nude mice than 
MCF7 controls (Figure 3.3E).  Many of the control tumors did not grow or disappeared by 15 
weeks post-injection.  This suggests that the c-Myb knock-down cell line is less estrogen-
dependent than the parental line given that no exogenous hormone was implanted in these 
mice.  This result also correlated with the observed tamoxifen resistance in the c-Myb knock-
down cells (Table 3.1).  
 A recent study found that the estrogen receptor can directly relieve transcriptional 
attenuation in the first intron of c-Myb, thus giving greater insight into how ER regulates c-
Myb expression (Drabsch et al., 2007).  The authors proposed that c-Myb is required for the 
proliferation of MCF7 cells because they observed decreased proliferation in c-Myb knock-
down MCF7 cells versus controls when treated with β-estradiol.  These results are 
contradictory to ours, where we observed increased growth and tumorigenesis in the c-Myb 
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knock-down line.  This may be in part due to our use of a more estrogen sensitive MCF7 cell 
line; unlike the cell line used by Drabsch et al., our MCF7 isolate requires estrogen to grow 
and in the absence of hormone (i.e. phenol-red free and charcoal stripped FBS media) they 
do not proliferate.  We were also able to show that the c-Myb knock-down cell line forms 
more colonies in vitro and grows faster in vivo, data not shown by these authors.   
 Our results from both human breast tumor microarray data and c-Myb knock-down in 
MCF7 cells suggest a novel tumor suppressor role for c-Myb in breast cancer.  In 
collaboration with Chad Deisenroth and Yanping Zhang (University of North Carolina), we 
identified a c-Myb target gene, Hep27 (DHRS2) (Rushton et al., 2003), as a novel regulator 
of the p53 pathway (Deisenroth, Thorner et al., submitted).  The Hep27 protein inhibits 
Mdm2, a well-known inhibitor of p53, thereby stabilizing the p53 protein (see pathway 
diagram below).  
 
 
 
 In MCF7 cells, when estrogen was added to the media, we observed a corresponding 
increase in both c-Myb and Hep27 (Figure 3.6A).  When c-Myb was exogenously expressed 
at increasing levels, there was a corresponding increase in Hep27 and p53 protein levels 
(Figure 3.6B).  Conversely, when c-Myb levels were depleted via shRNA, there were 
corresponding decreases in both Hep27 and p53 protein (Figure 3.6C).  Taken together, these 
results suggest the existence of this c-Myb-Hep27-p53 pathway in MCF7 cells.   
The SAM analysis of our MCF7 c-Myb knock-down line versus parental line showed 
that Hep27’s expression is significantly reduced in the knock-down line (data not shown).   
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Figure 3.6.  c-Myb induces p53 stabilization and activation in a Hep27 dependent 
manner. (A) 10 nM estradiol was added to media for 22 hours and cell lysate collected for 
western blot analysis.  (B) Expression construct expressing c-Myb was transfected into 
MCF7 cells for 24 hours and indicated proteins were detected by western blot. (C)  Western 
blot for c-Myb, p53, and Hep27 protein levels in MCF7 cells with c-Myb knock-down 
(shMYB) or control (shGFP).  
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Figure 3.7. 
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Figure 3.7.  Potential c-Myb-Hep27-Mdm2-p53 pathway in luminal breast cancer. The 
Miller et al., 2005 dataset (n=236) was classified into the breast tumor intrinsic subtypes 
(Basal-like, HER2-enriched, Luminal A, Luminal B, and Normal-like) using the PAM50 
predictor (Parker et al., 2009).  (A) Kaplan-Meier survival analysis of disease-specific 
survival stratified by subtype.  p-value determined by log-rank test, testing the null 
hypothesis that the survival curves are identical across the subtypes. (B) Hep27 mRNA 
expression in ER- and ER+ tumors (n=232).  p-values calculated by t-test showing different 
expression values across ER status or biologically defined breast tumor subtypes. (C) c-Myb 
and (D) Hep27 expression varies by intrinsic subtype.  (E) Hep27 expression in p53-mutant 
and p53-wild-type tumors.  (F) A p53-mutation signature (Troester et al., 2006) was applied 
to this dataset and correlated with breast tumor subtype.  For figures C-F, p-values were 
calculated by ANOVA, testing the null hypothesis that all group means are equal.   
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Again, this suggests that in luminal tumors the c-Myb-Hep27-p53 pathway may be intact 
and, therefore, tumors with higher levels of c-Myb will correspondingly have higher levels of 
stabilized, wild-type tumor suppressor p53.   To further investigate this, we analyzed the 
breast tumor microarray data of Miller et al. (Miller et al., 2005).  The tumors in this dataset 
are representative of all breast tumor subtypes and their prognosis (overall survival) is similar 
to patients in other breast tumor microarray datasets (Figure 3.7A).  We observed higher c-
Myb and Hep27 levels in ER+, p53 wild-type tumors, both common features of the Luminal 
breast tumor subtype (Figures 3.7B-D).  We also found that p53 wild-type tumors expressed 
higher levels of Hep27 (Figure 3.7E), and luminal tumors are least likely to be p53 mutant 
(Figure 3.7F).  Luminal tumors have been repeatedly observed as chemotherapy resistant 
(Parker et al., 2009; Rouzier et al., 2005), but until now the potential mechanism was 
unknown.  Here, our results showing c-Myb high-expressing tumors have poor pathological 
complete response to chemotherapy (Table 3.1) may be due to an intact c-Myb-Hep27-p53 
pathway in the luminal subtypes.   
The identification of a c-Myb signature was also informative from a possible 
developmental perspective.  As compared with the luminal tumor defining gene signature, we 
observed that more genes from the c-Myb gene list overlapped this cluster than other luminal 
defining gene lists (GATA3 and ER).  This is suggestive that the c-Myb transcription factor is 
potentially regulating many genes in luminal tumors. 
During hematopoiesis the expression of c-Myb is highest in progenitor cell lineages 
and is down-regulated during differentiation (Ramsay and Gonda, 2008).  We used a recent 
study that isolated four cell lineages in the normal mammary gland (Lim et al., 2009): 
stromal, mammary stem cell, luminal progenitor, and mature luminal populations.  
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Comparisons of our c-Myb gene signature, as well as the previously published GATA3 and 
ER gene signatures, to the Lim et al. data showed the opposite result for c-Myb in the 
mammary lineage when compared to the hematopoietic linage. Namely, the c-Myb gene 
signature significantly correlated with the mature luminal cell population, and was least 
expressed within the mammary stem cell enriched population (Figure 3.5).  In addition, the 
estrogen-regulated activity was highest in both luminal progenitor and mature luminal cells, 
while the GATA3-regulated activity was also highest in the mature luminal population, but 
was also increased in both the luminal progenitor and mammary stem cell populations 
(Figure 3.5C). 
Directly targeting c-Myb as a form of cancer therapy has been suggested and 
implemented in several tumor types (Calabretta, 1991; Ratajczak, 1992).  Based on positive 
results, an antisense oligonucleotide targeting c-Myb has been developed as a targeted 
therapeutic and a Phase I clinical trial begun for patients with advanced hematologic 
malignancies (National Clinical Trials Identifier: NCT00780052).  It has been suggested that 
this form of treatment could be of value in patients with other cancers expressing high c-Myb, 
including breast tumors (Ramsay and Gonda, 2008).  However, our findings indicate c-Myb 
is not behaving as an oncogene in ER+, luminal breast tumors, which is the most common 
form of human breast cancer.  Rather, c-Myb in the mammary gland is being expressed in the 
mature luminal cell population and acting in a pathway to stabilize the tumor suppressor, 
p53.  Therefore, high c-Myb expression is beneficial in luminal breast cancer and reducing c-
Myb protein levels via antisense therapy could be detrimental.  In total, our current findings 
have yielded unique insights into the role of c-Myb in luminal breast cancer and suggest that 
it is behaving as a tumor suppressor in this disease.   
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CHAPTER IV 
CONCLUSION 
 
 Over the past decade our understanding of breast cancer at the molecular level has 
significantly improved due, in part, to the identification of the breast tumor intrinsic subtypes 
by gene expression microarrays and other advances in genetics and cell biology. The intrinsic 
subtypes of breast cancer have been recapitulated in many labs using differing RNA 
collection techniques and varying microarray platforms (Herschkowitz et al., 2007; Hu et al., 
2006; Parker et al., 2009; Perou et al., 2000; Sorlie et al., 2001; Sorlie et al., 2003).  To date, 
at least six breast cancer subtypes have been identified including luminal A, luminal B, 
normal breast-like, HER2-enriched, basal-like, and claudin-low.  The subtypes not only have 
biological relevance but also clinical relevance, as each tumor type has unique clinical 
outcomes and response to treatment (Carey et al., 2007; Fan et al., 2006).  Several dominant 
genes drive the classification of the luminal and HER2-enriched tumor types, namely the 
expression of estrogen receptor/ESR1 (luminal), and amplification and high expression of 
HER2/ERBB2.  Other subtypes are defined by their lack of gene expression, such as in the 
claudin-low subtype where low expression of claudin genes 3, 4, and 7 is observed.  The 
basal-like subtype lacks expression of both the estrogen and progesterone receptors, as well 
as HER2. 
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 The molecular subtypes are defined by an intrinsic gene set (Hu et al., 2006; Perou et 
al., 2000).  The expression of these genes varies across the subtypes, but does not vary within 
replicates of the same patient sample.  Of the hundreds of genes that are used to classify each 
subtype, relatively few have been well defined in terms of their contribution to breast 
tumorigenesis.  Therefore, my research focused on the MYB family of transcription factors, 
which is a family comprised of three genes all found within the intrinsic gene set (Hu et al., 
2006).  Specifically, my goal was to evaluate the in vitro and in vivo function of B-Myb and 
c-Myb (two MYB family members with implications in tumorigenesis in other tissue types) 
in the mammary gland. 
 
B-Myb Gene in Breast Cancer Biology  
 High expression of B-Myb was observed in the proliferation gene signature, which is 
an easily identifiable and dominant gene signature that is a marker of tumor cell proliferation 
rates (Whitfield et al., 2002).  The proliferation genes are highly expressed in the both the 
luminal B and basal-like subtypes, and the fast proliferation of these tumor types may 
contribute to their poor prognoses.  Basal-like tumors have no known molecular therapeutic 
targets and at this time can only be treated with cytotoxic chemotherapy.  Therefore, I chose 
to focus on how B-Myb expression may be contributing to this relatively ill-defined subtype. 
 Using several large breast tumor microarray datasets we found B-Myb to be 
significantly highly expressed in the basal-like subtype followed by next highest expression 
in the luminal B and HER2-enriched subtypes, which are all tumor subtypes with poor 
outcomes.  We also determined that B-Myb expression levels alone were able to predict 
overall survival across all breast cancer subtypes as well as within the luminal A, luminal B, 
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and HER2-enriched tumors.  B-Myb expression levels were not capable of predicting survival 
within the basal-like tumors alone, however, patients with this disease have very poor 
outcomes and virtually all express high levels of this protein. 
 These results suggest that B-Myb expression is not only relevant in basal-like disease, 
but levels of B-Myb may play an important role in all subtypes.  For example, the luminal A 
tumors have the lowest expression of B-Myb relative to the other subtypes, yet the overall 
survival of patients with this subtype could be predicted using univariate analysis by B-Myb 
gene expression, suggesting that higher levels of B-Myb portends worse outcome. 
 High expression levels of B-Myb in basal-like disease has not been linked to genomic 
amplification (Bergamaschi et al., 2006).  This group identified amplification of the B-Myb 
locus (20q13) in luminal B tumors, but not in other breast cancer subtypes.  This indicates 
that the high expression of B-Myb in luminal tumors may be selected for and leads to poor 
outcomes, whereas in basal-like tumors its high expression is the result of other mechanisms, 
such as amplification of transcription factor(s) targeting B-Myb, enhanced promoter activity, 
or because of the inherent high proliferation rate of this tumor type. 
 B-Myb expression levels were also predictive of pathologic complete response.  We 
observed that patients with higher levels of B-Myb expression had a better response to 
chemotherapy.  At first glance this may appear counterintuitive, whereby tumors having the 
poorest outcomes have the best response to chemotherapy treatment.  This unusual finding 
has been observed before and been dubbed the “triple negative (basal-like) tumor paradox” 
(Carey et al., 2007).  The explanation for this paradox is that many highly proliferative basal-
like tumors (that show high B-Myb and proliferation-signature expression) are in fact 
chemotherapy sensitive, and these patients respond and have a good outcome; however, the 
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majority of basal-like patients (whose tumors are also highly proliferative) do not completely 
respond and have residual disease, and they have a high likelihood of recurrence, and in fact, 
they do recur at a high frequency.  Thus, some patients respond and do well, while most do 
poorly, thus the paradox.  
 Recently, a B-Myb germline variant causing a non-synonymous serine to glycine 
amino acid change at residue 427 (S427G, rs2070235) was identified as decreasing overall 
cancer risk when combining a variety of tumor types and comparing to non-cancer bearing 
controls (Schwab et al., 2007).  However, using a population-based case-control study from 
the Carolina Breast Cancer Study, we identified women carrying two copies of this variant 
and determined that they were at a two-fold increased risk of basal-like breast cancer, but not 
other breast tumor subtypes.  The disagreement between these two findings may be due to the 
different tumor types studied, or because the other study combined a variety of tumors 
whereas we studied breast tumors only.  We did not observe any increase or decreased risk in 
breast cancer as a whole and it wasn’t until we separated tumors into subtypes that we were 
able to observe the increased risk in only the basal-like subtype.   
Our findings mark the first published basal-like breast cancer risk variant.  It should 
also be noted that the frequency of the B-Myb variant is approximately 10-fold higher in 
African-Americans compared with Caucasians.  This is especially relevant in light of recent 
data showing that premenopausal African-Americans are approximately twice as likely to 
develop basal-like tumors compared with premenopausal Caucasians (Carey et al., 2006; 
Millikan et al., 2008).  It may be of potential benefit for African-Americans to be genotyped 
for this variant to identify carriers who would be ideal candidates for early and frequent 
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breast cancer screenings with the goal of earlier detection and diagnosis of basal-like breast 
cancer. 
 To evaluate the function of B-Myb’s role in chemotherapy response we used in vitro 
models of normal and tumor-derived mammary cell lines.  Normal mammary tissue derived 
lines and basal-like tumor derived lines expressing endogenous levels of B-Myb were 
compared to those overexpressing B-Myb, or the susceptibility variant.  Normal derived lines 
overexpressing B-Myb, or variant, were more sensitive to topoisomerase 2α (TOP2A)-
targeting chemotherapeutics, but not to the other drugs tested.  TOP2A inhibitors caused the 
enzyme to become trapped on double-strand DNA breakpoints, thereby causing G2 cell cycle 
checkpoint arrest.  B-Myb has been identified as a G2/M regulating gene and increased B-
Myb expression may be promoting the TOP2A-inhibitor-treated cells to continue to cycle via 
the G2 checkpoint through induction of downstream B-Myb target genes.  By facilitating 
cells through G2, with less regard for DNA damage, the B-Myb-overexpressing cells may 
attempt to cycle again, eventually leading to the observed increased sensitivity to TOP2A 
phenotype.  Using microarray analysis, TOP2A expression was increased in the TOP2A-
inhibitor treated cell lines overexpressing B-Myb.  Therefore, more of the target protein was 
present in these cells potentially leading to the observed increased sensitivity phenotype.  In 
support of this hypothesis, many known and potential B-Myb target genes were identified by 
cell cycle analysis and enrichment for G2/M cell cycle genes was observed.  This is in 
agreement with what has been observed in other tissue types, but had not been documented in 
the mammary epithelial cells. 
 The results of this study enhance our understanding of the role of B-Myb in breast 
cancer by identifying new B-Myb target genes, by showing that this gene is highly expressed 
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in basal-like breast cancers and that it is of prognostic value for survival and predictive value 
for pathological complete response.  B-Myb appears to not only be important in basal-like 
tumors, where highest expression is observed, but also in luminal tumors, where it was 
capable of predicting outcomes in these diseases that have relatively good prognosis. 
Currently the function of the B-Myb S427G variant is unknown, and we did not 
observe any gene expression differences between the wild-type and variant B-Myb, nor were 
differences in chemosensitivity identified.  Recent evidence has shown that the variant is 
more resistant to degradation than wild-type B-Myb (Schwab et al., 2007).  It is tempting to 
speculate that if the half-life of the variant is longer, carriers of this variant have more B-Myb 
protein in the cell leading to increased cell cycling with less regard to DNA damage.  A 
woman carrying two copies of the variant may, over her lifetime, accumulate a number of 
genetic mutations in her mammary cells eventually giving rise to basal-like disease.  One 
experiment to test this hypothesis would be to study mouse models of cancer crossed with B-
Myb variant knock-in mice and determine the effects this gene has on tumorigenesis. 
Clearly B-Myb, a gene found in the intrinsic gene set, plays a significant role in basal-
like disease and potentially in the aggressiveness of other breast tumor subtypes.  Its 
overexpression, combined with the frequent loss of p53 and Rb observed in basal-like disease 
(Derenzini et al., 2008; Herschkowitz et al., 2008; Sorlie et al., 2001), may begin to explain 
the basal-like paradox, and the B-Myb variant could be of future clinical importance for 
determining disease risk, especially in African-Americans. 
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c-Myb Gene in Breast Cancer Biology  
 The c-Myb oncogene has been linked to cancer since its discovery as the mammalian 
homolog of v-Myb, a transforming viral oncogene causing avian leukemia.  We observed 
significant high c-Myb expression in the ER-positive, luminal breast tumor subtypes.  This is 
in concordance with previous studies correlating high c-Myb protein levels in ER-positive 
breast cancer (Guérin M, 1990), and with c-Myb being a direct ER target gene (Drabsch et 
al., 2007).  However, the role of c-Myb in ER-positive breast cancer remains virtually 
unknown. 
 High c-Myb expression has been linked to poor overall survival in a variety of 
leukemias and colorectal cancer (Biroccio et al., 2001; Ramsay and Gonda, 2008).  These 
results are consistent with the fact that c-Myb was identified as an oncogene and we 
hypothesized that we would observe similar results in breast cancer; however, the results 
were markedly different.  Using multiple different breast tumor microarray datasets with 
patient survival information, we found that higher levels of c-Myb expression conferred 
better outcomes.  In fact, even within the luminal A subtype, a subtype with patients virtually 
all expressing high levels of c-Myb, we were able to stratify outcome based on c-Myb 
expression levels alone, suggesting a dosage effect (i.e. tumors with very high c-Myb 
expression levels portend better patient outcomes than those with high c-Myb expression 
levels).  High c-Myb expression also correlated with smaller tumor size and lower tumor 
grade.  This data indicated that the c-Myb oncogene may be playing a very different role, 
potentially as a tumor suppressor, in breast cancer compared to the previously studied tumor 
types.  
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 We chose to stably knock-down endogenous c-Myb protein levels in a luminal tumor 
cell line (MCF7) to assess the role of c-Myb in luminal breast tumorigenesis.  We found that 
when c-Myb levels were reduced the tumor grew faster, was more anchorage independent, 
and was able to form tumors in nude mice.  In general, when no exogenous estrogen (i.e. 
estrogen pellet) is added to nude mice, MCF7 cells grow very slowly or do not form tumors 
at all.  However, in the MCF7 cells were c-Myb levels were reduced, no estrogen was 
required for tumor growth; these results suggest that with lower levels of c-Myb, the tumor is 
less dependent on estrogen for growth.  In agreement with our patient survival data, these 
results demonstrated that having c-Myb expression in the tumor bestows a protective effect, 
precisely what one would observe with a tumor suppressor gene.  However, this begged the 
question how is this transcription factor behaving as a tumor suppressor in breast cancer? 
In collaboration with Dr. Yanping Zhang’s lab at UNC, we were able to 
experimentally determine that c-Myb was working in concert with a mitochondrial protein, 
Hep27, to regulate p53 stabilization in the luminal tumors.  Deisenroth et al. (submitted) 
described an interaction between Hep27 and Mdm2, a p53 inhibitor, whereby Hep27 inhibits 
Mdm2 function thereby stabilizing p53.  Therefore, as Hep27 protein levels increase, there is 
a corresponding increase in stable p53.  We, and others, have described Hep27 as a 
transcriptional target of c-Myb (Lei et al., 2004).  We showed that gradually increasing 
exogenous amounts of c-Myb to MCF7 cells resulted in a corresponding increase in Hep27, 
stable p53, and the p53 target gene, p21.  This suggests that a c-Myb-Hep27-p53 pathway 
exists in this luminal tumor cell line.  Furthermore, using a large human breast tumor 
microarray dataset we found evidence of the existence of this in vivo.   
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It has been established that luminal/ER-positive tumors respond poorly to 
chemotherapy, likely due to the fact that the overwhelming majority of these tumors are p53 
wild-type (Troester et al., 2006).  Furthermore, luminal tumors treated with chemotherapy 
also show increased p21 protein level post-treatment (Troester et al., 2004).  Our results 
demonstrate that the stability of p53 in this tumor type is actually dependent on ER and c-
Myb.  When c-Myb levels are increased, p53 is stabilized, and we see a corresponding 
upsurge in p21 levels. 
To further identify phenotypic differences between the c-Myb knock-down line and 
its parental control, we hybridized labeled mRNA to Agilent microarrays and performed 
significance analysis of microarrays (SAM).  Many gene expression differences were 
observed with over 1,200 transcripts (“c-Myb signature”) differentially expressed with a low 
false discovery rate.  These genes were capable of stratifying breast tumors into groups 
recapitulating their intrinsic subtypes, indicative of their unique expression across the tumor 
subtypes. 
A recent publication described the use of cell surface markers, EpCAM and CD49f, 
to isolate four discrete cell populations from the normal, human mammary gland: mammary 
stem cell enriched (MaSC), luminal progenitor, mature luminal, and stromal (Lim et al., 
2009).  This group used in vitro assays to show they had isolated the described cell types, and 
microarray gene expression analysis was also carried out on each cell type to identify unique 
gene expression profiles.  We used the gene expression data of Lim et al., 2009 to further 
analyze our c-Myb signature, as well as previous published gene signatures for ER and 
GATA3 (a transcription factor that is essential for mammary gland formation) (Oh et al., 
2006; Usary et al., 2004). 
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Our c-Myb gene list strongly correlated with the mature luminal gene profile, and was 
least correlated with the MaSC signature.  c-Myb expression levels alone displayed this same 
correlation.  This is in stark contrast to the observation in hematopoiesis, colonogenesis, and 
neurogenesis where c-Myb expression is highest in the stem cell populations and decreases 
and cells differentiate (Malaterre et al., 2007; Malaterre et al., 2008; Ramsay and Gonda, 
2008).  We observed the exact opposite expression pattern, lowest c-Myb expression levels in 
the MaSC population, increased levels in the luminal progenitor cells, and highest levels in 
the differentiated luminal cells.  Again, this highlights how differently c-Myb is behaving in 
the mammary gland versus other tissue types in which it has been studied.  Why this is the 
case is currently unknown, but we speculate that in the breast, c-Myb is under the strict 
control of the estrogen receptor, a hormone-responsive transcription factor that is not 
expressed in the hematopoietic system or the colon.  Also, differing transcriptional co-factors 
that are mammary tissue-specific may be interacting with c-Myb to promote transcriptional 
activation of different target genes in the mammary gland. 
The estrogen-regulated genes, and ESR1 expression alone, were also highest in the 
mature luminal population followed by having second highest expression in the luminal 
progenitor cells, and lowest expression levels in the MaSC population.  GATA3, a known 
target of ER and a gene essential in mammary development (Kouros-Mehr et al., 2006), was 
observed as having its highest expression in the luminal progenitor population; however, the 
GATA3 gene signature activity was observed highest in the mature luminal population.  
These results confirm previous observations that ER is not expressed in the MaSC population 
(Sleeman et al., 2007), and its expression begins in the luminal progenitor cells.  The ER 
targets GATA3 at this stage to promote proper mammary gland differentiation.  In the more 
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differentiated populations, the ER targets the transcription factor c-Myb, whose protein 
targets the activation of genes important for maintenance within the mature luminal cells, 
such as p53 via Hep27. 
The gene signature data presented above may have implications in hypothesizing the 
cell-of-origin for the luminal tumor subtypes.  Recent evidence proposes that the ER-
positive, luminal tumors arise from the mature luminal cell population in the mammary 
gland, whereas ER-negative tumors are derived from an earlier mammary cell lineage (Prat 
and Perou, 2009).  This is consistent with our findings that the ER-regulated activity and 
ESR1 expression was lowest in the MaSC population, but highest in the differentiated 
luminal cells.  Also, luminal tumors rarely mutated for p53, and in fact, the p53 pathway is 
most likely intact in this breast cancer subtype (Troester et al., 2006).  Here, we described 
that p53 stabilization in luminal tumors was likely due to an intact ER-c-Myb-p53 pathway, 
and our data showed that c-Myb expression and its downstream transcriptional-regulated 
activity was highest in the mature luminal population.  Further adding to this was our 
evidence that c-Myb’s expression, as well as its regulated activity, is highest in the luminal 
tumors and lowest in the ER-negative tumor subtypes. 
The c-Myb data presented here have very important clinical implications, especially 
in light of an ongoing clinical trial for patients with advanced hematologic malignancies 
(National Clinical Trials Identifier: NCT00780052).  The drug in this trial is a c-Myb 
antisense oligonuclotide given to patients with the intent of reducing the amount of c-Myb 
protein in the tumor.  It has been suggested that this form of treatment could be of value in 
patients with other cancers expressing high c-Myb, including breast tumors (Ramsay and 
Gonda, 2008).  However, c-Myb appears to be playing a tumor suppressor role in luminal 
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breast cancer, and treating patients with an antisense oligonucleotide against this gene could 
prove detrimental by leading to increased tumorigenesis. 
In summary, the MYB family of transcription factors including B-Myb and c-Myb, 
both identified as members of the intrinsic gene signature, are undoubtedly playing important 
roles in the etiology of breast cancer.  Our findings point to both genes as important markers 
of both breast cancer outcome and risk, particularly the B-Myb germline variant shown to 
cause increased risk of basal-like disease.  B-Myb is therefore a biomarker that is of potential 
clinical importance for determining disease risk and for guiding treatment.  The discovery of 
a tumor suppressor role for the c-Myb oncogene will greatly impact the future of luminal 
tumor treatment, notably the decision to expand a current clinical trial treating leukemia 
patients with antisense olionucleotides against c-Myb to breast cancer patients.  The work 
presented here begins to describe important genes from the intrinsic gene set, their 
involvement in breast tumorigenesis, and lays the groundwork for many future analyses. 
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APPENDIX II 
Genes expressed significantly higher, as determined by Significance Analysis of Microarrays (SAM), in doxorubicin-treated B-Myb 
overexpressing HME-CC cells versus doxorubicin-treated vector control cells.  A list of 217 genes with an FDR<3% was obtained 
and ranked based on fold-change. 
Genbank Accession # Fold Change Gene Name 
NM_002466 9.50 V-myb myeloblastosis viral oncogene homolog (avian)-like 2 
NM_017786 4.10 Hypothetical protein FLJ20366 
NM_018136 3.28 Asp (abnormal spindle)-like, microcephaly associated (Drosophila) 
NM_016343 3.21 Centromere protein F, 350/400ka (mitosin) 
NM_006528 3.08 Tissue factor pathway inhibitor 2 
NM_018131 3.07 Chromosome 10 open reading frame 3 
NM_001067 3.01 Topoisomerase (DNA) II alpha 170kDa 
NM_005733 2.99 Kinesin family member 20A 
AF108138 2.96 Chromosome 15 open reading frame 20 
NM_001786 2.88 Cell division cycle 2, G1 to S and G2 to M 
NM_014750 2.88 Discs, large homolog 7 (Drosophila) 
NM_006101 2.72 Kinetochore associated 2 
NM_001813 2.71 Centromere protein E, 312kDa 
NM_181803 2.71 Ubiquitin-conjugating enzyme E2C 
NM_004701 2.64 Cyclin B2 
NM_007174 2.63 Citron (rho-interacting, serine/threonine kinase 21) 
AK098670 2.62 Cell division cycle associated 2 
NM_022346 2.62 Chromosome condensation protein G 
NM_003258 2.58 Thymidine kinase 1, soluble 
ENST00000330382 2.56  
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Genbank Accession # Fold Change Gene Name 
NM_018101 2.56 Cell division cycle associated 8 
NM_019013 2.55 Hypothetical protein FLJ10156 
NM_030919 2.52 Chromosome 20 open reading frame 129 
NM_001389 2.51 Down syndrome cell adhesion molecule 
NM_007280 2.51 Opa-interacting protein 5 
NM_006845 2.49 Kinesin family member 2C 
NM_006461 2.47 Sperm associated antigen 5 
NM_003318 2.47 TTK protein kinase 
NM_080668 2.47 Cell division cycle associated 5 
NM_005192 2.46 Cyclin-dependent kinase inhibitor 3 (CDK2-associated dual specificity phosphatase) 
NM_031966 2.45 Cyclin B1 
NM_012484 2.45 Hyaluronan-mediated motility receptor (RHAMM) 
K03200 2.45  
NM_004336 2.43 BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) 
NM_018685 2.41 Anillin, actin binding protein (scraps homolog, Drosophila) 
NM_002358 2.35 MAD2 mitotic arrest deficient-like 1 (yeast) 
NM_005480 2.33 Trophinin associated protein (tastin) 
NM_024734 2.27 Calmin (calponin-like, transmembrane) 
BC000784 2.25 Baculoviral IAP repeat-containing 5 (survivin) 
NM_002875 2.23 RAD51 homolog (RecA homolog, E. coli) (S. cerevisiae) 
BC032409 2.22 CDNA clone IMAGE:5217021, with apparent retained intron 
NM_005563 2.21 Stathmin 1/oncoprotein 18 
NM_001827 2.19 CDC28 protein kinase regulatory subunit 2 
AL832427 2.16 Fanconi anemia, complementation group D2 
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Genbank Accession # Fold Change Gene Name 
BC030154 2.15 Ribonucleotide reductase M2 polypeptide 
AK024476 2.15 CTF18, chromosome transmission fidelity factor 18 homolog (S. cerevisiae) 
NM_177978 2.11 Chordin 
NM_025245 2.10 Pre-B-cell leukemia transcription factor 4 
NM_018451 2.09 Centromere protein J 
NM_006596 2.07 Polymerase (DNA directed), theta 
NM_032117 2.06 GAJ protein 
AB058697 2.06 Hypothetical protein FLJ10719 
NM_015341 2.04 Barren homolog (Drosophila) 
NM_138555 2.04 Kinesin family member 23 
NM_022092 2.03 CTF18, chromosome transmission fidelity factor 18 homolog (S. cerevisiae) 
NM_031217 2.02 Kinesin family member 18A 
BC046178 2.02 CDNA clone IMAGE:4452583, partial cds 
THC1572841 2.01  
NM_012112 2.00 TPX2, microtubule-associated protein homolog (Xenopus laevis) 
NM_005879 1.98 TRAF interacting protein 
NM_032997 1.97 ZW10 interactor 
NM_033316 1.97 Antigen p97 (melanoma associated) identified by monoclonal antibodies 133.2 and 96.5 
NM_017915 1.97 Hypothetical protein FLJ20641 
NM_014791 1.97 Maternal embryonic leucine zipper kinase 
AK094154 1.96 CDNA FLJ36835 fis, clone ASTRO2010996 
AK097948 1.94 Hypothetical protein FLJ40629 
NM_020242 1.94 Kinesin-like 7 
NM_002129 1.93 High-mobility group box 2 
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Genbank Accession # Fold Change Gene Name 
BC044933 1.92 Hypothetical protein LOC146909 
NM_015426 1.92 DKFZP434C245 protein 
NM_173466 1.91 Hypothetical protein DKFZp434P055 
AL137347 1.90 Hypothetical protein DKFZP761M1511 
NM_003600 1.90 Serine/threonine kinase 6 
NM_013277 1.90 Rac GTPase activating protein 1 
NM_014321 1.89 Origin recognition complex, subunit 6 homolog-like (yeast) 
NM_006479 1.88 RAD51 associated protein 1 
ENST00000317847 1.87  
NM_005030 1.87 Polo-like kinase 1 (Drosophila) 
NM_004636 1.86 Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3B 
NM_001826 1.86 CDC28 protein kinase regulatory subunit 1B 
BC041395 1.85 Homo sapiens, Similar to diaphanous homolog 3 (Drosophila), clone IMAGE:5277415, mRNA 
NM_052969 1.85 Ribosomal protein L39-like 
NM_003981 1.84 Protein regulator of cytokinesis 1 
NM_001992 1.84 Coagulation factor II (thrombin) receptor 
BC046178 1.84 CDNA clone IMAGE:4452583, partial cds 
I_3537291 1.84  
AK001581 1.83 Hypothetical protein FLJ10719 
NM_013239 1.82 Protein phosphatase 2A 48 kDa regulatory subunit 
NM_013277 1.82 Rac GTPase activating protein 1 
NM_002266 1.81 Karyopherin alpha 2 (RAG cohort 1, importin alpha 1) 
NM_004848 1.81 Chromosome 1 open reading frame 38 
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NM_016448 1.80 RA-regulated nuclear matrix-associated protein 
NM_000057 1.80 Bloom syndrome 
NM_005496 1.80 SMC4 structural maintenance of chromosomes 4-like 1 (yeast) 
NM_182687 1.80 Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase 
NM_003878 1.80 Gamma-glutamyl hydrolase (conjugase, folylpolygammaglutamyl hydrolase) 
NM_018492 1.79 T-LAK cell-originated protein kinase 
AI791206 1.79 MRNA (fetal brain cDNA g6_1g) 
NM_152259 1.79 Leucine-rich repeat kinase 1 
BC035696 1.79 Similar to RIKEN cDNA 2700049P18 gene 
NM_145061 1.78 Chromosome 13 open reading frame 3 
NM_021077 1.78 Neuromedin B 
AB006624 1.78 KIAA0286 protein 
X85137 1.78 Kinesin family member 11 
NM_000227 1.78 Laminin, alpha 3 
ENST00000320402 1.75  
NM_018454 1.75 Nucleolar and spindle associated protein 1 
NM_145018 1.75 Hypothetical protein FLJ25416 
NM_024629 1.74 MLF1 interacting protein 
XM_293746 1.73  
NM_006187 1.73 2'-5'-oligoadenylate synthetase 3, 100kDa 
THC1410715 1.73  
BC005970 1.73 Vaccinia related kinase 1 
NM_003579 1.73 RAD54-like (S. cerevisiae) 
NM_007294 1.72 Breast cancer 1, early onset 
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NM_021874 1.71 Cell division cycle 25B 
ENST00000325544 1.71  
NM_018098 1.70 Epithelial cell transforming sequence 2 oncogene 
NM_015161 1.70 ADP-ribosylation factor-like 6 interacting protein 
NM_152521 1.70  
NM_004260 1.69 RecQ protein-like 4 
NM_018098 1.69 Epithelial cell transforming sequence 2 oncogene 
NM_014109 1.69 ATPase family, AAA domain containing 2 
NM_000356 1.68 Treacher Collins-Franceschetti syndrome 1 
NM_012291 1.68 Extra spindle poles like 1 (S. cerevisiae) 
NM_003920 1.67 Timeless homolog (Drosophila) 
NM_024918 1.67 Chromosome 20 open reading frame 172 
NM_018186 1.67 Hypothetical protein FLJ10706 
NM_003686 1.66 Exonuclease 1 
AW082201 1.66  
NM_024094 1.65 Defective in sister chromatid cohesion homolog 1 (S. cerevisiae) 
NM_002106 1.65 H2A histone family, member Z 
NM_138419 1.65 Family with sequence similarity 54, member A 
AK056691 1.65 Haspin 
NM_004843 1.64 Interleukin 27 receptor, alpha 
NM_016195 1.64 M-phase phosphoprotein 1 
NM_002452 1.63 Nudix (nucleoside diphosphate linked moiety X)-type motif 1 
NM_032883 1.63 Chromosome 20 open reading frame 100 
NM_018369 1.62 DEP domain containing 1B 
 112 
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AB046816 1.61 KIAA1596 
NM_031942 1.61 Cell division cycle associated 7 
NM_002106 1.61 H2A histone family, member Z 
NM_001255 1.61 CDC20 cell division cycle 20 homolog (S. cerevisiae) 
NM_025108 1.60 Hypothetical protein FLJ13909 
AA470111 1.59 
Similar to protein phosphatase 2A 48 kDa regulatory subunit isoform 1; 
serine/threonine protein phosphatase 2A, 48kDa regulatory subunit; PP2A, subunit B, 
PR48 isoform; PP2A B subunit PR48; NY-REN-8 a 
NM_030928 1.59 DNA replication factor 
NM_002916 1.59 Replication factor C (activator 1) 4, 37kDa 
AK027267 1.59 RAS-like, family 11, member B 
NM_001254 1.59 CDC6 cell division cycle 6 homolog (S. cerevisiae) 
I_3512484 1.59  
NM_012177 1.58 F-box protein 5 
AK075134 1.58 Cell division cycle associated 7 
NM_018132 1.58 Chromosome 6 open reading frame 139 
ENST00000329801 1.58  
BC010176 1.57 Similar to RIKEN cDNA 2410004L22 gene (M. musculus) 
NM_004523 1.57 Kinesin family member 11 
XM_302460 1.56  
NM_024808 1.56 FLJ22624 protein 
ENST00000332692 1.56  
U79240 1.56 PAS domain containing serine/threonine kinase 
NM_017760 1.56 More than blood homolog 
NM_002388 1.55 MCM3 minichromosome maintenance deficient 3 (S. cerevisiae) 
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NM_005483 1.55 Chromatin assembly factor 1, subunit A (p150) 
NM_004111 1.55 Flap structure-specific endonuclease 1 
NM_014176 1.54 HSPC150 protein similar to ubiquitin-conjugating enzyme 
ENST00000325202 1.54  
NM_014708 1.54 Kinetochore associated 1 
NM_014865 1.54 Chromosome condensation-related SMC-associated protein 1 
NM_003914 1.54 Cyclin A1 
AB028070 1.53 Activator of S phase kinase 
I_2001857 1.52  
AL117629 1.52 DKFZP434C245 protein 
NM_005441 1.52 Chromatin assembly factor 1, subunit B (p60) 
NM_138639 1.52 BCL2-like 12 (proline rich) 
BC045739 1.51 Chromosome 15 open reading frame 23 
NM_024037 1.51 Hypothetical protein MGC2603 
THC1562595 1.51  
NM_016095 1.51 DNA replication complex GINS protein PSF2 
NM_007086 1.50 WD repeat and HMG-box DNA binding protein 1 
NM_014220 1.50 Transmembrane 4 superfamily member 1 
NM_000121 1.49 Erythropoietin receptor 
NM_004526 1.49 MCM2 minichromosome maintenance deficient 2, mitotin (S. cerevisiae) 
I_2011745 1.49  
NM_173083 1.48 Lin-9 homolog (C. elegans) 
NM_004629 1.47 Fanconi anemia, complementation group G 
NM_173553 1.47 Hypothetical protein FLJ25801 
 114 
Genbank Accession # Fold Change Gene Name 
NM_014256 1.47 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3 
NM_018087 1.46 Hypothetical protein FLJ10407 
NM_003503 1.46 CDC7 cell division cycle 7 (S. cerevisiae) 
NM_006437 1.45 Poly (ADP-ribose) polymerase family, member 4 
NM_014505 1.45 Potassium large conductance calcium-activated channel, subfamily M, beta member 4 
BC021694 1.45 Adducin 3 (gamma) 
AK024475 1.45 DKFZP434I216 protein 
NM_001197 1.44 BCL2-interacting killer (apoptosis-inducing) 
NM_001237 1.44 Cyclin A2 
NM_145249 1.43 Family with sequence similarity 14, member B 
NM_016824 1.43 Adducin 3 (gamma) 
NM_005914 1.43 MCM4 minichromosome maintenance deficient 4 (S. cerevisiae) 
NM_005342 1.43 High-mobility group box 3 
BC018086 1.42 Similar to RIKEN cDNA A430101B06 gene 
NM_175923 1.42 Hypothetical protein MGC42630 
AK000898 1.41 Zwilch 
NM_002915 1.41 Replication factor C (activator 1) 3, 38kDa 
AK055071 1.41 Phosphatidylinositol glycan, class K 
NM_018455 1.40 Uncharacterized bone marrow protein BM039 
NM_018140 1.40 Centrosomal protein 72 kDa 
NM_000169 1.40 Galactosidase, alpha 
THC1519373 1.39  
AF117229 1.39 Protein x 0004 
THC1551878 1.38  
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Genbank Accession # Fold Change Gene Name 
NM_014467 1.38 Sushi-repeat-containing protein, X-linked 2 
BC039021 1.37 CDNA clone IMAGE:6043059, partial cds 
NM_007047 1.37 Butyrophilin, subfamily 3, member A2 
I_932423 1.35  
AK074989 1.35 Hypothetical protein BC007899 
AF258562 1.34 Deoxythymidylate kinase (thymidylate kinase) 
THC1579998 1.34  
 
